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1. INTRODUCTION 
Many drugs can exist in different solid-state forms (e.g., crystalline, amorphous, 
hydrates/solvates, co-crystals). Given forms differentiate from each other by the 
arrangement of molecules towards each other in three-dimensional (3D) space. 
In case of crystalline material the molecules have very well defined three 
dimensional long range arrangement in 3D space whereas the amorphous form 
is defined by the lack of long range order of molecules. The solvates are crys-
talline matter that contains solvent molecules in a host crystal lattice. In case of 
crystal hydrates water molecules are incorporated to the structure.  
Due to different arrangement of molecules towards each other, given solid 
state forms have different physicochemical properties. Most important to phar-
maceutical processes are the differences in the dissolution rate, solubility and 
physical stability. Less stable forms have usually faster dissolution and higher 
apparent solubility compared to the more stable forms at given conditions. The 
possibility to obtain supersaturated solution and faster dissolution rate is the 
main benefit which can be obtained by using less stable solid state forms.  
As amorphous form is usually thermodynamically very unstable several dif-
ferent formulation-based and processing-based approaches have been proposed 
in order to stabilize it. One of the methods used is a solid dispersion approach. 
Given method involves dispersing the active pharmaceutical ingredient (API) in 
a suitable carrier, which is usually a hydrophilic polymer. The kinetic barrier or 
reduced molecular mobility and specific interactions between the carrier poly-
mer and drug molecules are the two factors that can stabilize the solid disper-
sions. 
In case of metastable crystalline solid state forms, adding amphiphilic poly-
mers to solutions has been shown to have a good stabilizing effect. The amphi-
philic polymers can absorb to crystals and thus stabilize them. As metastable 
solid state forms can produce supersaturated solutions towards the most stable 
form, the amphiphilic polymer molecules can stabilize the metastable form also 
through solubilization process which lowers the degree of supersaturation and 
hence the driving force to crystallization. 
It is known that introducing water to the metastable solid state forms can 
compromise the stability even further. Thus it is important to study the effect of 
aqueous media and water vapour to the physical stability of solid state forms. 
As during pharmaceutical processes the drug substance(s) are also often ex-
posed to water and elevated temperatures which can lead to water-mediated 
process induced transformations (PITs), it is essential to monitor the solid state 
form also during processing. Present thesis is aiming to gain further knowledge 
and understanding on these topics. 
Present research work focused on investigating the solid state forms of 
piroxicam (PRX) and its possible phase transformations during processing and 
storage. The different solid state forms studied were PRX anhydrate form I 
(AH), PRX monohydrate (MH), and amorphous solid dispersion of PRX and 
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Soluplus® in 1 to 4 weight ratio (SD). In order to determine the effect of Solu-
plus® as an excipient in a formulation, also the respective physical mixture of 
AH and Soluplus® (PM AH) was studied. The aim of this study was to gain 
understanding about the effects of different solid-state forms of a poorly water-
soluble PRX on the drug dissolution and oral bioavailability in rats. Also the 
stability of different solid state forms in a relevant dissolution medium was 
studied. The second aim of the present study was to carry out qualitative and 
quantitative analysis of the physical solid-state stability of the SD during stor-
age. The third aim was to study the stability of PRX solid state forms during a 
pharmaceutical process that involves exposition of material to water and ele-
vated temperatures. 
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2. LITERATURE REVIEW 
2.1. Solid state forms and their properties 
Many drugs can exist in different solid-state forms (e.g., crystalline, amorphous, 
hydrates/solvates, co-crystals). Given forms differentiate from each other by the 
arrangement of molecules towards each other in three dimensional (3D) space 
(Chieng et al., 2011; Lu and Rohani, 2009). In case of crystalline material, the 
molecules have very well defined 3D long range arrangement built up by fixed 
repeating unit cells which form a crystal lattice (Lin, 2015). The polymorphism 
can be defined as the ability of any compound to crystallize in more than one 
distinct crystal structures. Thus the polymorphic forms are solid state forms that 
differentiate from each other by the arrangement and/or confirmation of mole-
cules in crystal lattice (Aaltonen et al., 2009). If the crystal structure is built up 
by host molecules that contain guest molecules, the resulting solid is called co-
crystal or solvate depending on the state of guest molecule in ambient condi-
tions. If the guest molecule is solid in ambient conditions the solid is called co-
crystal and in case of liquid the resulting solid is called solvate (Vishweshwar et 
al., 2006). If the adducted molecule is water the resulting solid is called hydrate. 
It is noteworthy that the solvates/hydrates can also exhibit polymorphism 
(Aaltonen et al., 2009). The amorphous form is defined by the lack of long 
range ordered arrangement of molecules (Hilden and Morris, 2004). 
Due to different arrangement of molecules in the lattice, the solid state forms 
can have different properties (Datta and Grant, 2004). Among others the differ-
ences can be found in unit cell volume (only in case of crystalline matter), den-
sity, refractive index, hygroscopicity, melting point, enthalpy, entropy, free 
energy, solubility, spectroscopic properties, dissolution rate, stability, surface 
free energy, interfacial tensions, crystal habit, hardness, flowability and com-
pactability (Aaltonen et al., 2009; Vippagunta et al., 2001). As given properties 
affect the processability (tableting, granulation etc.) and the release of the active 
pharmaceutical ingredient (API) from dosage form, it is vital to use the most 
suitable solid state form (Hickey et al., 2007). Since different solid state forms 
have different stabilities, the metastable forms can convert to the most stable 
form at given conditions. Thus it is also vital to monitor the solid state form 
stability during manufacture and storage (Byrn et al., 1995). Possible solid state 
phase transitions include polymorphic interconversions, hydrate-anhydrate 
transformations, order-disorder transformations and polyhydrate interconver-
sions (Hickey et al., 2007).  
Among the properties of solid state forms the aqueous solubility and disso-
lution rate are crucial as they can have a direct impact on the bioavailability of a 
polymorphic drug after oral administration (Aaltonen et al., 2009; Newman and 
Byrn, 2003). To date, several studies have been reported on oral administration 
and bioavailability of different solid-state forms of drugs both in humans and 
animals (Hurst et al., 2007; Janssens and Van den Mooter, 2009; Vasconcelos et 
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al., 2007). The first pioneering work on the influence of solid state forms to 
bioavailability was reported by Aguiar et al., who described the effect of 
chloramphenicol palmitate polymorphism on bioavailability (Aguiar et al., 
1967). As the number of poorly water soluble APIs and drug candidates has 
been growing significantly during past decade (Buckley et al., 2013) new and 
novel methods that can improve the dissolution characteristics have been 
searched for and thus also the interest in different solid state forms has grown. If 
the oral absorption of a drug is solubility-limited, one could use more soluble 
solid-state form(s) to achieve the systemic exposure required for therapy 
(Huang and Tong, 2004; Singhal and Curatolo, 2004). The difference in solubil-
ity and dissolution rate arise from the different bonding strength of molecules in 
different solid state forms. Usually the smaller is the bonding energy between 
the molecules at given conditions the faster is the dissolution and the higher is 
the probability of obtaining supersaturated solution. Unfortunately this also 
means that the solid state forms which are dissolving faster are less stable and 
tend to recrystallize as more stable and less soluble forms (Burger and 
Ramberger, 1979). Little attention, however, has been paid on the potential 
solid-state transformations after oral administration, and subsequent impli-
cations on the bioavailability of drugs. In addition, the effect of excipients on 
the performance of different solid-state forms has not been very much studied. 
As different solid state forms can have different dissolution profiles and 
bioavailability, it is important to monitor the solid-state stability of metastable 
and amorphous materials during storage (Weuts et al., 2005). Since different 
excipients (polymers) can have quite specific interactions with drug molecules 
(Wen et al., 2008), it is also important to study how excipients affect in vitro 
and in vivo dissolution behavior of solid state forms. The physical instability of 
metastable and amorphous materials has to be taken into an account during the 
formulation of these materials (Janssens and Van den Mooter, 2009). 
 
2.1.1. Crystalline polymorphs 
Different polymorphs can be obtained by changing the crystallization conditions 
like temperature, solvents where crystallization takes place, and additives in 
crystallization medium (Llinàs and Goodman, 2008). Also interconversions 
between polymorphic forms are possible when pressure is applied during 
tableting and grinding. For example, given transformations have been shown to 
take place in case of paracetamol (Boldyreva et al., 2002). Due to the different 
arrangement of the molecules in crystal lattice, the polymorphs can also have 
different properties (Sheth and Grant, 2005). For example the differences in unit 
cell usually manifest also in different crystal habits. As with other solid state 
forms the most stable polymorph at given conditions is usually the least soluble. 
This arises from the difference of bonding strength between the molecules 
making up the crystal lattice. The most stable polymorphs have the strongest 
bonding between the molecules at given conditions (Chemburkar et al., 2000). 
4
14 
Polymorphs can be classified as enantiotropes and monotropes, depending 
on whether or not the interconversion can take place reversively. In case of the 
monotropic polymorphic forms only one of the polymorphic forms is stable at 
all conditions. In case of enantiotropic polymorphic forms different poly-
morphic forms are stable at different temperatures below melting temperature. 
In case of monotropic systems there is only one stable polymorph below melt-
ing temperature and all metastable forms will recrystallize to given form over 
time or when they are subjected to temperature corresponding to their melting 
point (Sheth and Grant, 2005). The recrystallization of metastable polymorphic 
forms as stable forms in solid state are mechanistically rather complex reac-
tions, and their kinetics is usually described by Arrhenius type equations (Lin, 
2015). Because of the activation energy associated with them, the solid-solid 
transformations are kinetically hindered and they occur only at the temperature 
that provides the system with sufficient thermal energy to cross the activation 
energy barrier (Lohani and Grant, 2006). 
The crystallization itself is a multi-step process which includes nucleation 
and subsequent crystal growth. In the solutions the driving force for crystalli-
zation arises from supersaturation. The prerequisite of crystallization is the for-
mation of stable nucleus, which is dependent on the volume free energy that 
favors aggregation and the surface free energy that favors dissolution of the 
molecular clusters. Given two factors are dependent on the size of the nucleus. 
The bigger the nucleus the smaller is the influence of surface free energy and 
thus more stable is the nuclei. Thus, there is a critical radius of nuclei above 
which it is stable. The activation energy barrier related to obtaining this state 
can be overcome in supersaturated solutions (Lohani and Grant, 2006; 
Rodr??guez-Sponga et al., 2004). Once there is presence of stabile nuclei in the 
solution, the process of crystal growth starts. As the nucleation and crystal 
growth compete for solute in terms of their respective dependence on super-
saturation, the rates of given processes determine the crystal size. Crystal 
growth is dependent on internal factors such as three dimensional structure of 
the crystal and external factors such as temperature, solvent and degree of 
supersaturation. Mechanistically the growth process involves several steps 
through which the growth unit pass. These include the transport from the bulk 
of the solution to the site at crystal surface, adsorption of the growth unit onto 
the impingement site, diffusion from the impingement site to growth site and 
incorporation to crystal lattice. Each of given steps can be rate-limiting 
depending on the internal and external factors (Rodriguez-Hornedo and 
Murphy, 1999). It is also vital to mark that the optimum conditions for nuclea-
tion and crystal growth may not be the same (Yu, 2001). 
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2.1.2. Crystal hydrates 
The crystal hydrates can be classified by the way the water molecules are incor-
porated in 3D space relative to host molecules. In case of isolated site hydrates 
the water molecules are isolated from each other by host molecules and in case 
of channel hydrates the water molecules sit next to each other in rows (Gillon et 
al., 2003). The amount of solvent or water molecules per host molecule can be 
stoichiometric or nonstoichiometric (Sheth and Grant, 2005). The properties of 
hydrates are closely related to the arrangements of molecules. In case of isolated 
site hydrates the removal of water can usually happen only when the overall 
structure is broken up whereas in case of channel hydrates the dehydration can 
also take place without breaking up the host crystal lattice. Thus the water re-
moval is more easily facilitated in case of channel hydrates. This also means 
that the dehydration of the channel hydrates can occur at lower temperatures 
(Petit and Coquerel, 1996).  
As the hydrates are the most stable solid state forms in aqueous media, they 
are the least soluble and other forms tend to transform to those. This means that 
hydrates can be obtained by mixing anhydrous solid state forms with water. The 
stability of hydrate form arises from the properties of water molecules. The 
water molecules stabilize the crystal lattice as they have small size and multi-
directional hydrogen bonding capability (Aaltonen et al., 2009; Gillon et al., 
2003). The hydrate formation in solution can take place as solid to solid trans-
formation or it can be solution mediated. In case of channel hydrates both 
processes could take place, while for isolated hydrates it is more common that 
the hydrate formation is solution mediated. In case of isolated site hydrate for-
mation the structure of anhydrate form has to be broken up, while the tunnel 
hydrate can be formed by simply absorbing water (Datta and Grant, 2004; 
Zhang et al., 2004). In case of solution mediated process the overall crystal-
lization process of hydrate from solutions follows the same basic principles as 
the crystallization of anhydrates.  
 
2.1.3. Amorphous materials 
Solid material may by intrinsically amorphous at ambient conditions. For 
example polymers like polyvinylpyrrolidone (PVP) and polyethylenglycole are 
in amorphous form at room temperature. (Craig et al., 1999). This is the case for 
molecules that pack poorly or have many internal degrees of freedom. Kineti-
cally the slow crystallization rate will result in material becoming “frozen liq-
uid” without crystallization (Yu, 2001). One general cause of the physical sta-
bility of given amorphous materials arises from conformational flexibility of 
given molecules (Yu et al., 2000). However the amorphous form is ther-
modynamically unstable for most of the small organic molecule APIs and can 
only be obtained by special production methods. For example quench-cooling 
of the melt, mechanical activation (via ball-milling), rapid precipitation from 
solution and continuous concentration processes (e.g., lyophilization or spray-
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draying) have been used for obtaining amorphous form (Hilden and Morris, 
2004). Amorphous forms can also be formed accidentally during processing, 
examples including milling, compression and drying (Craig et al., 1999). The 
lack of crystal structure means that amorphous materials are physically unstable 
and they tend to crystallize over time in case of small organic molecule API-s. 
On the other hand that also means that they have higher solubility and fastest 
dissolution rate compared to other solid state forms (Hancock and Parks, 2000). 
Lack of structure also means that amorphous materials are more hygroscopic 
compared to other solid state forms (Aaltonen et al., 2009). 
As the amorphous form does not have a crystal structure it does not have a 
definite melting point. One of the more important properties of amorphous solid 
is a glass transition temperature (Tg). Tg is a temperature where the material 
goes from rubbery state to brittle glassy state. In glassy state the rotational and 
translational motions of molecules are greatly reduced while the bonding 
remains similar to the liquid state. Thus the glass transition is characterized by a 
step change of heat capacity of given material (Craig et al., 1999). Due to 
increased molecular motions above Tg, the probability of crystallization is also 
significantly higher (Craig et al., 1999; Hancock and Zografi, 1997). The 
overall nucleation and crystal growth theory also applies to amorphous to crys-
talline conversion (Hancock and Zografi, 1997; Yu, 2001). It has to be noted 
that the Tg of the mixtures is dependent on the Tg of the components according 
to Gordon-Taylor equation (Craig et al., 1999). Thus adding a component with a 
low Tg will compromise the stability of the component with higher Tg. As the 
Tg of water is approximately –135 °C and it can be quite easily absorbed by 
amorphous materials, the high humidity can compromise the physical stability 
of given material (Craig et al., 1999; Haque and Roos, 2008; Heljo et al., 2012).  
 
2.1.4. Water mediated solid state transformations and  
their impact on the performance of active  
pharmaceutical ingredients 
Although amorphous and metastable polymorphic forms have solubility and 
dissolution benefits, their instability during storage and in the presence of 
aqueous media (gastric fluid and dissolution environment) could lead to the 
recrystallization of crystalline form with lower solubility. Hydrate formation 
during dissolution testing has been reported with many drugs (Aaltonen et al., 
2006; Alonzo et al., 2010; Lehto et al., 2009; Paaver et al., 2012) and amor-
phous drugs are extremely prone to this kind of solid-state transformation. It has 
to be emphasized that given solid-state transformations may also occur during 
the drug absorption in vivo. To date, the consequences of such solid-state 
changes on oral bioavailability are not fully understood (Greco and Bogner, 
2011). Possible solid-state transformations to a less stable form during dis-
solution could lead to an unexpectedly low bioavailability. Hence, if the trans-
formation takes longer to occur, the estimated dissolution and bioavailability 
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could be achieved with a less stable amorphous form. These phenomena have 
not been thoroughly investigated in the literature, and there are no direct corre-
lations between in vitro and in vivo performance of metastable solid forms. 
Therefore it is important to study the in vivo absorption of the drugs that exhibit 
solid-state transformations during in vitro dissolution. 
Also the exposure of the API to water and high temperature during pharma-
ceutical processes could present higher risks for process induced transfor-
mations (PITs) in the solid-state of drugs and/or excipients which in turn may 
ultimately affect the processability and final dosage form quality and per-
formance (Morris et al., 2001; Nikowitz et al., 2013; Zhang et al., 2004). 
Several recent reports provide evidence that unexpected solvent-mediated trans-
formations of APIs may be induced, especially during manufacturing of phar-
maceuticals in wet conditions and/or in high relative humidity. For example, 
given transformations have occurred during wet granulation (Airaksinen et al., 
2005; Jørgensen et al., 2002). Also dissolving or suspending the drug in an 
aqueous liquid during coating can greatly increase the potential for PITs to 
occur through the solution or solution-mediated mechanisms (Zhang et al., 
2004). These types of PITs include polymorphic transformations, hydration/ 
dehydration, and/or amorphous crystallization. For example, the hydration of 
drugs typically proceeds via solution or solution-mediated mechanisms, and 
different hydrate forms can differ markedly from each other with respect to their 
physical, chemical, and biological properties (Sheth et al., 2004c; Zhang et al., 
2004). In addition, the rapid water removal during coating or drying phase of 
wet granulation may result in fast crystallization of a metastable crystal form of 
drug, or may lead to the formation of an amorphous phase in the drug layer via 
the solution mechanism (Zhang et al., 2004). The kinetics of the possible phase 
transitions (such as solution-mediated transformations, solvate formation) in 
aqueous-based manufacturing processes determines whether or not the PITs will 
be completed during the time scale of the process (Morris et al., 2001). 
 
 
2.2. Amorphous solid dispersions 
The solid dispersion approach has been successfully used to stabilize the mate-
rials in amorphous form. Given method involves dispersing the API in a suit-
able carrier, which is usually a hydrophilic polymer (Leuner and Dressman, 
2000). This kind of stabilization method was first used by Sekiguchi et.al. 
(Sekiguchi and Obi, 1961). While the pioneering works used small well soluble 
molecules, nowadays amphiphilic polymers are usually applied as carrier poly-
mers (Leuner and Dressman, 2000). For example synthetic polyvinyl polymers 
and polyethylene glycols have been successfully used as carriers in pharma-
ceutical solid dispersions since they have significant inhibitory effects on the 
crystallization of drugs both in solution and solid state (Gupta et al., 2004). 
5 
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The kinetic barrier or reduced molecular mobility and specific interactions 
between the carrier polymer and API are the two factors that can stabilize the 
solid dispersions (Vasconcelos et al., 2007). For example the main mechanisms 
of crystallization inhibition in solid state have been reported to be due to the 
antiplasticizing effect of the polyvinyl polymer (e.g., PVP), and steric and spe-
cific interactions occurring between the drug and PVP (Khougaz and Clas, 
2000). As molecular mobility governs the diffusion and surface integration, it 
influences the phase separation and subsequent crystallization of solid dis-
persions (Janssens and Van den Mooter, 2009). The nucleation and crystal 
growth require correct orientation and conformation of the molecules, both of 
which are also governed by the molecular mobility. Furthermore, the number of 
contacts between the molecules that lead to the formation of hydrogen bonds 
depend on the molecular mobility (Janssens and Van den Mooter, 2009). Hence, 
the probability of crystallization is lower if the system has lower molecular 
mobility. 
Some small molecules are known to increase the molecular mobility of 
amorphous systems (by acting as plasticizers), and they can cause the crys-
tallization (Hancock and Zografi, 1994; Heljo et al., 2012; Janssens and Van 
den Mooter, 2009). For hydrophilic polymers, the water is well known to act as 
a plasticizer (Blasi et al., 2005; Lai et al., 1999). The hydrogen bonding and 
specific interaction between carrier polymer and API has been shown to stabi-
lize the solid dispersions (Bhugra and Pikal, 2008). Formation of the hydrogen 
bonds between an API and polymer can inhibit the formation of hydrogen 
bonds between two API molecules. Also the relative bonds strength in the 
crystalline API compared to the hydrogen bonds in solid dispersion can affect 
the thermodynamic crystallization driving force (Janssens and Van den Mooter, 
2009). As hydrogen bonding between an API and polymer can inhibit the dif-
fusion of API molecules, it is evident that this also affects the molecular mo-
bility (Bhugra and Pikal, 2008). 
In addition to the effect on physical stability of the solid state form, the 
amorphous solid dispersions may also improve the apparent solubility of the 
poorly soluble drug molecules. (Brouwers et al., 2009). Since SDs approach 
aims at improving the solubility and dissolution of drugs, it is foremost effective 
in enhancing the bioavailability of drugs belonging to biopharmaceutical classi-
fication system (BCS) Class II which have low solubility and high permeability 
(Kawabata et al., 2011). Amorphous solid dispersions generate high or even 
supersaturated concentrations of poorly soluble drugs by increasing their 
apparent solubility and dissolution rate. In addition, the hydrophilic carrier 
polymer can increase the wettability and surface area available for dissolution. 
Hydrophilic carrier polymers used in solid dispersions can also inhibit the pre-
cipitation by reducing the degree of supersaturation of the solutions (Brouwers 
et al., 2009). 
In conclusion, the SD approach is a promising formulation strategy to improve 
the oral bioavailability of poorly water-soluble drugs (Janssens and Van den 
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Mooter, 2009; Kawabata et al., 2011; Vasconcelos et al., 2007) since APIs 
formulated in SDs have a higher physical stability compared to pure amorphous 
compounds and they still have a faster dissolution compared to their crystalline 
counterparts. The other advantage of the SDs over the pure amorphous 
compounds is that the carrier polymer can solubilize the poorly water-soluble 
compound during dissolution and thus inhibit the crystallization.  
 
 
2.3. Properties of piroxicam 
Piroxicam (PRX) was used as a poorly soluble polymorphic drug in this study. 
PRX is a well-known long-acting non-steroidal anti-inflammatory drug used in 
the treatment of rheumatic disease.  
 
          
Figure 1. a) Chemical structure of piroxicam anhydrate form I (AH). b) Chemical 
structure of piroxicam monohydrate. The arrows show internal rotations about the C8–
C9 and N10–C11 bonds. 
 
Since PRX has such a low water solubility and high permeability, it belongs to 
class II in BCS (Amidon et al., 1995). PRX has two pKa values: pKa1=1.86 and 
pKa2 = 5.46 (Jinno et al., 2000). PRX has four known crystal forms: PRX 
anhydrate form I (AH), II, III and PRX monohydrate (MH) (Kogermann et al., 
2011; Vre?er et al., 2003). The chemical structures of AH and MH are shown 
on Figure 1a and Figure1b, respectively. PRX can also be converted to the 
amorphous form. Pure amorphous PRX has been reported to be very unstable 
(Kogermann et al., 2011; Sheth et al., 2004a; Sheth et al., 2004b; Sheth et al., 
2004c) and it transforms quickly to MH in a dissolution medium (Naelapää 
et al., 2012). The PITs associated to the ball milling and cryomilling, melt spin-
ning and nanocrystallization of PRX have been widely reported (Drebushchak 
et al., 2006; Kogermann et al., 2011; Lai et al., 2011; Shakhtshneider et al., 
2007; Sheth et al., 2004c). It has been reported that the solubility of AH in arti-
fical gastric fluid at 37 ºC is 184.9 mg/l and that the solubility of MH in the 
same conditions is 84.5 mg/l (Vre?er et al., 2003). Also it is known that AH has 
faster dissolution and higher solubility compared to a MH in solutions with 
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biorelevant pH. It is well known that all anhydrous polymorphic forms of PRX 
(AH, II and III) can undergo the solid-state transformation to PRX MH (Jinno et 
al., 2000; Naelapää et al., 2012; Sheth et al., 2004c). In water, AH recrystallizes 
as a MH, and at room temperature it takes more than one hour for this process 
to start (Paaver et al., 2012). In MH the PRX is in the zwitterionic form (with 
ZZZ configuration) which structure differs significantly from anhydrous forms 
(with EZE configuration) by internal rotations about the C8–C9 and N10–C11 
bonds and by proton transfer from O17 to N16 (Kojic-Prodic and Ruzic-Toros, 
1982; Reck et al., 1988; Reck and Laban, 1990; Taddei et al., 2001). According 
to the Sheth et al. (2004c), the dehydration behaviour of MH is consistent with 
its underlying crystal structure, which is characterized by the absence of tunnels 
and a complicated hydrogen-bond network (Sheth et al., 2004c). Since AH and 
MH have completely different unit cells, it is obvious that the AH dissolves in a 
dissolution medium before it can recrystallize as a MH. It could be expected 
that different solid-state forms could also show different rate and extent of dis-
solution and oral bioavailability. Hence possible solid-state transformations that 
could also occur during dissolution in vivo can decrease the bioavailability of a 
better dissolving form. The same applies to PITs and solid state transformations 
that occur during storage. Thus it is important to monitor the stability of solid 
state of API and excipients during processing, dissolution and storage. 
 
 
2.3. Properties of Soluplus® 
As the instability of amorphous PRX is well known the solid dispersion 
approach was chosen in order to stabilise it in this study. Polyvinyl-
caprolactame-polyvinylacetate-polyethyleneglycole graft copolymer (Solu-
plus®) was used as a carrier polymer. This is a novel hydrophilic pharmaceutical 
excipient that is specially tailored to be applied as a carrier polymer in the SDs 
of poorly water-soluble APIs.  
 
 
Figure 2. Chemical structure of Soluplus® 
 
To date Soluplus® has been successfully used to obtain SD-s of several different 
API-s (Djuris et al., 2013; Linn et al., 2012; Nagy et al., 2012; Shamma and 
Basha, 2013). The average molecular weight of Soluplus® is in the range of 
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90 000 to 140 000 g/mol. Soluplus® has relatively low Tg of 68 °C (Lim and 
Hoag, 2013), and to date it has been mostly used for preparing SDs by melting 
method. Soluplus® is known to absorb water readily from air: at 40% relative 
humidity (RH) its water content is about 4% and at 75% RH about 12% by 
weight in ambient room temperature . Soluplus® has a lower critical solution 
temperature of 40 °C, and adding electrolytes to the aqueous solutions of Solu-
plus® can result in lower critical solution temperature and cause its salting out 
(Hughey et al., 2013). 
 
 
 2.5. Common analytical techniques  
used in solid state form analysis 
The physical characterization of solid state forms can be performed with many 
different techniques which enable to analyse different properties (Aaltonen et 
al., 2009). Perhaps the oldest method used for characterization of solid state 
forms and especially the crystalline matter is optical microscopy. In its basic 
form it enables to register the crystal habit. By using polarized light microscopy 
it is possible to determine the optical properties of the material. Also amorphous 
form can be distinguished from crystalline material with given technique (Alonzo 
et al., 2010). It is also possible to study solid state transformations with optical 
and polarized light microscopy when the hot stage accessory is used (Rustichelli 
et al., 2000). The optical microscopy can be substituted with methods that have 
much higher magnification such as scanning electron microscopy (SEM) and 
atomic force microscopy (Danesh et al., 2001; Rasenack and Muller, 2002). 
Single crystal X-ray diffractometry is indispensable in studying crystalline 
material as all crystalline materials have distinctive diffraction pattern. As the 
diffraction pattern arises from constructive interference of the X-rays diffracted 
from crystal planes, given analytic tool enables to determine the unit cell con-
stants. As it can be relatively hard to obtain single crystals that are large enough 
to carry out single crystal X-ray diffraction experiment, one could use X-ray 
powder diffraction method (XRPD) (Yu et al., 2003). This method is also capa-
ble of distinguishing the amorphous form from crystalline solid state forms, 
since amorphous materials display amorphous halo instead of diffraction pattern 
(Newman et al., 2008). 
Thermal methods are also quite often used in the characterization of solid 
state forms. The differential scanning calorimetry (DCS) is suitable for defining 
the changes in enthalpy, melting temperatures, Tg-s and dehydration tempera-
tures. The DSC can be used for detecting the interaction between the API and 
excipients as interaction can change the given properties. Also given properties 
can be used for the identification of different solid state forms as these are mate-
rial properties that are related to the interaction of the molecules in solid state 
(Chadha and Bhandari, 2014). Also thermogravimetry is useful additional tech-
nique that can be used in studying the behaviour of the crystal hydrates as it 
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enables to determine the weight loss upon dehydration (Han and Suryana-
rayanan, 1998). 
The vibrational spectroscopy techniques (mid-infrared spectroscopy, near-
infrared spectroscopy, pulsed terahertz spectroscopy and Raman spectroscopy 
are extremely useful in differentiating all solid state forms from each other as 
they are probing the inter- and/or intra-molecular bond vibrations (Bugay, 2001; 
Kogermann et al., 2007b). In addition, Raman and near-infrared spectroscopy 
carry the benefit of being applicable as process analytical technology tools since 
these methods do not need the preliminary sample preparation. Thus they can be 
used for detecting the solid state transformations during different pharma-
ceutical processes (Yu et al., 2004). 
Solid state nuclear magnetic resonance spectroscopy is another method that 
has become quite common tool for studying the solid state forms in recent 
years. Given technique can be applied to very different kinds of analytical work 
ranging from polymorph identification and quantification to a final dosage form 
characterization. It is also possible to use it in order to distinguish amorphous 
material from crystalline material and detect the interactions between the solid 
state forms and excipients (Stephenson et al., 2001; Tishmack et al., 2003). 
 
 
2.6. Multivariate data analysis methods- tools  
for monitoring the solid state stability 
The interest in multivariate data analysis methods has substantially increased 
over the past decade due to the application of vibrational spectroscopic methods 
as process analytical tools. A number of multivariate data analysis methods 
coupled with vibrational spectroscopy have been successfully employed in the 
analysis of solid-state transformations of APIs (Aaltonen et al., 2007b; De Beer 
et al., 2009; Kogermann et al., 2008; Kogermann et al., 2007a; Kogermann et 
al., 2011; Naelapää et al., 2012; Paaver et al., 2012; Romero-Torres et al., 
2007).  
 
2.6.1. Principal component analysis 
Principal component analysis (PCA) has been used in the qualitative analysis of 
solid-state forms during storage stability tests (Kogermann et al., 2011). PCA is 
a multivariate statistical analysis tool that can be used for data compression and 
information extraction. PCA finds combinations of variables that describe the 
major trends in the data set. Mathematically the PCA carries out eigenvector 
decomposition of the covariance or correlation matrix of the process variables 
(Wise et al., 1999). Thus in case of PCA the dimensions of the X matrix which 
corresponds to the number of X-variables are reduced to a fewer set of mutually 
orthogonal variables best describing the systematic variance in the data. Given 
new variables are uncorrelated with each other and they are called principal 
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components (PC). Each PC is the product of samples-score vectors and vari-
ables-loading vector. Plotting two score vectors against each other will give the 
positions of samples in that respective PC direction and plotting the loading 
vectors will describe the relationship between the original variables and the PC 
in question. Combining the scores and loadings plots will give the information 
on how the samples will behave compared to each other (Aaltonen et al., 2009; 
Abdi and Williams, 2010). 
 
2.6.2. Multivariate curve resolution 
For quantification of the solid-state transformations of APIs, partial least 
squares (PLS) regression has been successfully exploited (Aaltonen et al., 
2007a; Paaver et al., 2012; Stephenson et al., 2001). The quantification of amor-
phous systems, however, can be challenging since most of multivariate analysis 
methods used for analysing spectroscopic data need the calibration model based 
on the instrumental measurements of calibration mixtures. As amorphous mate-
rial can readily recrystallize when coming in contact with a crystalline matter, a 
method which does not need calibration models would be needed in order to 
carry out quantitative analysis. One method which can be used for this purpose 
is multivariate curve resolution (MCR). This method does not require a pre-
liminary measurement of mixtures with specific composition (Christensen et al., 
2013). The MCR mathematically decomposes instrumental responses of mix-
tures into the contributions of pure components and calculates the concentration 
profiles of them. In case of MCR alternating least squares (MCR-ALS), the 
equation of MCR is solved iteratively by using alternating least squares method 
(Tauler, 1995). While MCR is commonly used to obtain the quantitative infor-
mation of the reagents during chemical reactions (de Juan and Tauler, 2006; 
Ruckebusch and Blanchet, 2013), lately it has been successfully used also in 
studying complex phase transitions of APIs during dehydration (Christensen et 
al., 2013) and freeze-drying (De Beer et al., 2007). The general theory and 
application of MCR-ALS as a quantitative analysis tool for solid mixtures has 
been discussed in several papers (Azzouz and Tauler, 2008; Garrido et al., 
2004; Garrido et al., 2008). 
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3. AIMS OF THE STUDY 
The main goal of the present study was to investigate the water-mediated solid 
state transformations of a poorly water-soluble model drug piroxicam (PRX) 
that may occur during pharmaceutical processing and storage. Furthermore, to 
reveal and understand the biopharmaceutical relevance of these solid state 
transformations in vitro and in vivo. The specific aims of the study were: 
 
1. to prepare and characterize the different solid state forms of PRX (I, II, III) 
2. to gain understanding about the effects of different solid-state forms of PRX 
on the in vitro dissolution (I, II, III) and to determine the physical stability of 
PRX solid state forms in dissolution medium (I) 
3. to compare the in vivo bioavailability of different solid-state forms (AH vs 
MH vs amorphous PRX in a solid dispersion with polyvinylcaprolactame-
polyvinylacetate-polyethylene-glycole graft copolymer (Soluplus®) (SD)) of 
a model drug PRX after oral administration to rats (I). 
4. to investigate the physical solid-state stability of SDs of PRX and Soluplus® 
during a short-term storage in different humidity and temperature conditions 
and to determine the effect of possible crystallization on the dissolution of 
stored SDs (II). 
5. to carry out qualitative and quantitative analysis of the physical solid-state 
stability of the SDs of PRX and Soluplus® (II). 
6. to investigate the effects of aqueous drug-layer coating process of pellets 
(Cellets®) on the solid state forms of PRX in the miniaturized coating 
equipment and with free films and to determine the coating efficiency (III). 
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4. MATERIALS AND METHODS  
4.1. Materials 
Piroxicam (PRX) was used as a poorly water-soluble and polymorphic model 
drug. PRX anhydrate I (AH) was purchased from Letco Medical, Inc., USA. 
PRX monohydrate (MH) was obtained by recrystallization from water (Koger-
mann et al., 2007a). Soluplus® (polyvinyl caprolactam – polyvinyl acetate – 
polyethylene glycol graft copolymer) with a molecular weight range of 90000 – 
140000 g/mol was obtained from BASF SE Pharma Ingredients & Services, 
Ludwigshafen, Germany. Tenoxicam was purchased from Sigma-Aldrich 
Corporation. Ketamin (Bioketan inj 100 mg/ml 10 ml) was purchased from 
Vetoquinol S.A., Lure Cedex, France. Hydroxypropyl methylcellulose (HPMC, 
Methocel E5) was purchased from Dow Chemicals, Midland, MI, USA. 
Microcystalline cellulose (MCC) neutral pellets (Cellets®) with the particle size 
distribution of 1000–1400 μm were obtained from Syntapharm Harke Group, 
Gesellschaft für Pharmachemie mbH, Germany. All other reagents were 
purchased from Sigma-Aldrich Co. and used without any further purification. 
Size number 1 and 3 hard gelatin capsules (PosilockTM, Elanco, USA) were 
used in in vitro dissolution tests. Purge gasses were obtained from Eesti AGA 
AS, Tallinn, Estonia. 
 
4.2. Methods 
4.2.1. Preparation of physical mixtures and  
solid dispersions (I, II, III) 
Solid dispersion of AH and Soluplus® 1:4 (SD) was prepared using a solvent 
evaporation method (Tantishaiyakul et al., 1999). Soluplus® and AH were first 
dissolved in acetone. After evaporating the solvent at 40 ºC, the resulting SD 
was gently ground using a mortar and pestle. Four different ratios of PRX and 
Soluplus® were studied: 1:1, 1:2, 1:3, and 1:4. The 1:4 ratio was the first that 
resulted in amorphous PRX, therefore it was chosen for further investigation. 
Physical mixture (PM) of AH and Soluplus® 1:4 was obtained by mixing them 
in a mortar with pestle using geometric dilution. 
All PRX samples were passed through a 150 μm sieve. The solid-state forms 
were prepared one day before in vitro and in vivo experiments. AH, PM and SD 
were stored in a desiccator at ~0% relative humidity (RH) under reduced 
pressure at room temperature. MH was stored at ~54% RH at room temperature. 
The SDs of PRX and Soluplus® (1:4 weight ratio) for storage stability study 
were prepared by the following modified solvent evaporation method: 5 g of 
AH and 20 g of Soluplus® were dissolved in 250 ml of acetone. The solvent was 
evaporated at 40 ºC by using a Rotovapor® rotatory evaporator (Büchi, Switzer-
land). The rotation speed of the 1000-ml flask was set at 120 rpm. The SDs 
formed a solid foam which was removed from a flask using spatula and milled 
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gently by using mortar and pestle. After this the sample was placed under vacuum 
(50 mbar). All samples were passed through a 150-μm sieve. 
 
4.2.2. Storage stability study (II) 
The samples were investigated immediately after preparation and within regular 
time periods during a short-term (6-month) aging at the following storage 
conditions: ~0% RH / 6 °C (“low humidity-low temperature”), ~0% RH / 25 °C 
(“low humidity-intermediate temperature”), ~40% RH / 25 °C (“intermediate 
humidity-intermediate temperature”), and ~75% RH / 25 °C (“high humidity-
intermediate temperature”). The stability study protocol involved ten sampling 
time-points after preparation: one day (1D), two days (2D), four days (4D), one 
week (W1), two weeks (W2), three weeks (W3), four weeks (4W), two months 
(2M), three months (3M), six months (6M). Raman spectroscopy and ATR-
FTIR spectroscopy were used for the solid-state and drug-polymer interaction 
analyses of samples. 
 
4.2.3. Preparation of coating suspensions (III) 
The HPMC solution (5% w/w) was prepared as follows: approximately half of 
the calculated amount of distilled water (45 g) was heated (70 °C), and the 
polymer (5 g) was added to the hot distilled water under magnetic stirring. After 
the polymer was thoroughly dispersed, the remaining cold distilled water (50 g) 
was added, and the solution was continuously stirred for 48 hours before use. In 
order to obtain coating suspensions (50 g), the HPMC solution was loaded with 
different solid-state forms of PRX as follows: (1) 4% (w/w) AH in 5% (w/w) 
HPMC solution; (2) 4% (w/w) MH in 5% (w/w) HPMC solution; and (3) 10% 
(w/w) SD (2% (w/w) PRX) in 5% (w/w) HPMC solution. In case of SD, the 
coating suspension was charged with a drug load only half of that used with the 
other PRX solid state forms (since Soluplus® would have made the suspension 
too viscous to be sprayed). 
 
4.2.4. Preparation of the free films (III) 
Free films were prepared with an in-house set-up using a rotating plate made of 
Teflon and two drying heating units. A schematic diagram of the system is 
presented in Figure 3.  
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Figure. 3. A rotating plate set-up for preparing drug-loaded free films. Key: A. drying 
heating unit (60 W lamp), B. Raman spectrometer probe, C. drying heating unit (air 
flow unit), D. rotating Teflon plate, E. sample cups in the rotating plate. 
 
The sample size for each film was 2 ml and a coating suspension was applied to 
the sample cups in the rotating plate. Two opposite cups were used for each 
drying cycle. In the next phase, rotating plate was turned on and both heating 
units (lamp and air flowing device) were switched on. The rotation speed of the 
plate was adjusted to 1.0 rpm. The air flow rate was 5 m/s and the output of the 
lamp was 60 W. The distance between the rotating plate and the lamp was 
2.0 cm and between air flow unit and the plate 25 cm. The temperature at the 
sample level of the plate was 40 °C ± 2 °C. Raman spectra were measured from 
both of the samples. The spectra were also collected every 10 minutes during 
the drying phase. The distance between the Raman probe and sample was less 
than 1 mm. After the films were dried, they were gently removed from the 
sample cups using a spatula in order to carry out the differential scanning 
calorimetry (DSC) analysis. 
 
4.2.5. Drug-layer coating of microcrystalline cellulose pellets (III) 
The MCC neutral pellets (Cellets®) were drug-layer coated in a miniaturized 
top-spray air-suspension coating apparatus (Caleva Mini Coater, Caleva Process 
Solutions Ltd., Dorset, UK). Each small-scale coating batch comprised 20 g of 
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pellets. Film-coating parameters were adjusted as follows: inlet airflow rate  
4–6 m/s, air flow temperature 30 °C, vibration 17 Hz, amplitude 17 mm, 
atomising air pressure (drum) 0.5 bar, height of spray nozzle 130 mm, and the 
flow rate of a coating suspension 35 ml/h. The walls of the coating chamber 
were pretreated with Tween 40 (10% solution in water) before the experiments 
to avoid the sticking of the pellets. Both uncoated and drug-layer coated pellets 
were weighed with analytical balance (d=0,1mg) (AB54, Mettler-Toledo Inter-
national Inc., Switzerland) and the weight increase (%) and coating efficiency 
(%) was calculated (Table 1, see paragraph 5.4.2). In this study, “coating 
efficiency” was defined as a ratio of the weight gain of the coated pellets to the 
mass of the coating material added to the process. From the given ratio the 
coating efficiency (%) was calculated. The pellets were coated for 5 minutes 
followed by a 1-minute drying period. These cycles were repeated three or more 
times. Total coating time was 15 minutes for AH and MH, and 30 minutes for 
SD drug-layer coating. For Raman spectroscopy analysis and dissolution tests, 
the drug-layer coated pellet samples were collected at 5, 10, 15 and 30 minutes. 
In the prolonged drug-layer coating experiments (with a total coating time of 
1 hour), multiple samples were taken at 10, 20, 30 and 60 minutes. In case of 
AH and MH loaded coatings, the theoretical amounts of coating after 15 and 
60 minutes were 3.8% (w/w) and 15.2% (w/w) of the total weight of the pellets, 
respectively. In case of SD loaded coatings, the theoretical amount of coating 
after 30 minutes was 11.6% (w/w) of the total weight of the pellets.  
 
4.2.6. Raman spectroscopy (I, II, III) 
All solid-state forms of PRX were verified with Raman spectroscopy (BWS415 
i-Raman Miniature Raman Spectrometer, B&W TEK inc., USA) equipped with 
a peltier-cooled CCD detector (2048x64), two-fiber coaxial optic probes and a 
300-mW diode laser source operating at 785 nm. The analytical range was from 
175 cm–1 to 3100 cm–1. A total of 3 spectra with an integration time of 12 seconds 
were recorded from each sample. During slurry experiments, in-line Raman 
spectra were collected using the same parameters at a five-minute interval.  
Raman spectroscopy analysis of storage stability study was performed using 
a Kaiser Raman PhAT spectrometer (Kaiser areospace &electronics company, 
USA) equipped with a RXN1-PhAT-785-D laser with 20 mW nominal power 
operating at 785 nm, PhAT system probe head (nominal focal length 250 mm, 
nominal beam diameter at focal position 6 mm, focal tolerance +/– 12mm) and 
CCD detector (1024x256 EEV MPP type) with minimum operating temperature 
at –50 °C. HoloGRAMS software was used for preliminary data processing. 
The useful analytical wavelength region ranged from approximately 200 cm–1 to 
1920 cm–1 and the integration time of 0.5 second was used. 
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4.2.7. Fourier-transform infrared (FTIR) spectroscopy (I, II) 
ATR-FTIR spectroscopy was performed on powders using a IRPrestige-21 
spectrophotometer (Shimadzu Corp., Kyoto, Japan) and Specac Golden Gate 
Single Reflection ATR crystal, (Specac Ltd., Orpington, U.K). The analytical 
range was from 600 cm–1 to 4000 cm–1. 
ATR-FTIR spectroscopy analysis of storage stability study samples was 
performed using a Vertex 70 FTIR spectrophotometer (Bruker AXS GmbH, 
Germany) and MIRacleTM single reflection ATR crystal (Pike Technologies, 
Inc., USA). The analytical range was from 600 cm–1 to 4000 cm–1, resolution 
was 4 cm–1 and a total of 70 scans were taken from each sample. Opus 5.5 prog-
ramme was used for preliminary data processing.  
 
4.2.8. X-ray powder diffractometry (XRPD) (I, III) 
XRPD analysis was performed using a Bruker D8 Advanced diffractometer (D8 
Advance, Bruker AXS GmbH, Germany) with Ni filtered Cu K?1 radiation 
(?=1.5406Å, 40 kV and 40 mA) and using 0.3° divergence slit, two 2.5° Soller 
slits and LynxEye line detector. Samples were measured in Bragg Brentano 
reflection mode in the 2?–range 3 ? 50°, with the step size of 0.01° 2?. A total 
counting time of 8.8 seconds per step was used. The operating current and 
voltage were 40 mA and 45 kV, respectively. Experimental results were 
compared to the theoretical patterns in the Cambridge Structural Database 
(CSD, Cambridge, UK) (Allen, 2002). Refcodes BIYSEH (Kojic-Prodic and 
Ruzic-Toros, 1982), and CIDYAP01 (Bordner et al., 1984) were used as 
reference crystal structures, for AH, and MH, respectively. 
 
4.2.9. Differential scanning calorimetry (DSC) (I, III) 
Non-isothermal DSC was performed with a differential scanning calorimeter 
with refrigerated cooling system (DSC 4000, Perkin Elmer Ltd, Shelton, CT, 
USA). The DSC system was calibrated for temperature and enthalpy using 
indium as a standard. Samples were analyzed under dry nitrogen purge in 
crimped aluminium pans with 2 pinholes in a lid at a heating rate of 
10 °C/minutes from 30 to 210 ºC. Temperatures are given as onset temperatures 
of the events unless mentioned otherwise. 
 
4.2.10. Scanning electron microscopy (SEM) (III) 
Particle size and surface morphology of the samples were investigated using 
HeliosTM NanoLab 600 (FEI Company, Hillsboro, Oregon USA) high-
resolution scanning electron microscope (HR-SEM). Samples were mounted on 
aluminum stubs with silver paint and magnetron sputter coated with 3 nm gold 
layer in argon atmosphere prior to imaging. Pellets were measured using 75× 
and 175× magnification. 
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4.2.11 Dissolution studies (I, II, III) 
Dissolution tests were carried out in a Distek Dissolution system 2100B 
(Distek, Inc., North Brunswick, New Jersey, USA) dissolution test apparatus 
using USP basket method. The samples were automatically taken with minipuls 
3 peristaltic pump (Gilson, Middleton, WI, USA) and analyzed in-line with 
Uvikon spectrophotometer 922 (Kontron instruments, Ltd., Buckinghamshire, 
UK) at 354 nm. The extinction coefficient of PRX at given wavelenght was 
1.5379×104 M–1 cm–1. It was confirmed that Soluplus® did not show any 
absorption at 354 nm at used concentration. The dissolution medium was 
900 ml hydrochloric acid buffer (pH 1.2) (USP XXVIII) at 37 °C. The stirring 
rate was set to 50 rpm. Hard gelatin capsules (size 3) filled with 20 mg of AH, 
MH or equivalent amount of SD (mesh size 150 μm) were used for the 
dissolution testing of different PRX powder forms. Hard gelatin capsules (size 
1) filled with 500 mg of drug-layer coated pellets were used for the dissolution 
tests of drug-layer coated pellets. All samples were tested immediately after 
preparation and dissolution tests were performed at least in triplicate. 
In case of storage stability study the in vitro dissolution tests were performed 
using a paddle method (USP apparatus 2) and a Sotax AT7 (Switzerland) 
dissolution apparatus. In the dissolution experiments, 900 ml of hydrochloric 
acid buffer (pH 1.2) at 37 °C was used as the dissolution medium at a 
temperature of 37±0.5 ºC. Dissolution tests were performed in triplicate. 
Samples (3 ml, replaced) were withdrawn with a syringe at ten minutes 
intervals. After removal, the samples were immediately filtered through 
cellulose filters with a pore diameter of 45 μm and measured with a UV 
spectrophotometer (UV-1600PC Spectrophotometer, VWR International Europe) 
using an analytical wavelength of 354 nm. 
 
4.2.12. Intrinsic dissolution testing (I) 
Intrinsic dissolution testing was carried out using a Sotax 7A dissolution 
apparatus and Wood’s intrinsic dissolution test apparatus (Sotax AG, Switzer-
land). 0.1 g of PRX solid-state forms were compressed into the die using a 
tabletop hydraulic press and 392.6 MPa of pressure for 30 seconds. The 
intrinsic dissolution rate (IDR) test was performed using the same experimental 
parameters as in the conventional dissolution tests described above. The solid-
state form of the samples after the intrinsic dissolution test was verified by 
using Raman spectroscopy. 
 
4.2.13. Slurry experiments (I) 
In order to determine the possible phase transformations of PRX in hydrochloric 
acid buffer (pH 1.2) during dissolution testing, slurry tests were performed. Total 
2 g of anhydrous PRX sample or PRX mixtures (AH/PM AH/SD) were dispersed 
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in 5 ml of hydrochloric acid buffer (pH 1.2). Continuous mixing (300 rpm) was 
performed using magnetic stirrer and in-line Raman spectra were collected. 
 
4.2.14. Pharmacokinetic studies (I) 
Experiments were approved by the Ministry of Agriculture Ethical Committee 
for Animal Experimentation. 12 male Wistar rats, weighing 250–300 g were 
obtained from Harlan laboratories, Sweden. At the start of the experiment the 
rats were nine weeks old. Rats were randomly divided into two groups, each 
with six animals. The first group was given AH and the second group MH by 
the oral route. After washout period, the first and second groups were given SD 
and PM AH, respectively. Prior to all experiments animals were fasted 
overnight, water was given ad libitum. Before oral administration of different 
solid-state forms of PRX, rats were anesthezised with ketamin. Each rat was 
given 20 mg/kg of AH/MH or equivalent amount of PRX mixtures dispersed in 
1 ml of water with intragastric gavage. The dispersion of different solid-state 
forms of PRX in water took place within one minute prior to oral administration 
in order to minimize the possibility of solid-state form transformations in vitro. 
0.2 ml of blood was taken from lateral tail vein in the following time points: 0, 
15, 30, 60, 90, 120, 180, 480, 720 minutes after drug administration. Samples 
were mixed with 0.02 ml of 3.8% sodium-citrate solution and centifuged at for 
10 minutes at 3500g (RCF). Plasma was separated from sedimented cells with a 
pipet. Samples were storaged deep frozen at –75 ºC. 
 
4.2.15. Piroxicam assay (I) 
Plasma samples were analyzed using a high performance liquid cromatography 
(HPLC) system as described by Gwak et al., 2005 (Gwak et al., 2005). The 
HPLC system consisted of a Shimadzu Prominence LC 20AD pump and 
Shimadzu Prominence SPD M20A PDA detector set at 230 nm. A base de-
activated octadecylsilyl (ODS) column (Luna, 4.6mm × 250mm, 5μm, Pheno-
menex, USA) was eluted with a mixture of 0.05 M phophate buffer (pH 3.0) 
and acetonitrile (60:40 v/v) at a flow rate of 1 ml/minutes and at 40 ºC. After 
melting, 0.05 ml of plasma was taken from each sample and 0.15 ml of 
tenoxicam solution (250 μg/ml) was added to the sample as an internal standard. 
Thereafter 0.2 ml of 0.1 N HCl solution was added and samples were then 
extracted with 7 ml of diethyl ether for three minutes using Vortex mixer. Tubes 
were centrifuged for 10 minutes at 1100g (RCF), and after that the organic layer 
was separated and back-extracted with 0.2 ml of 0.02 N sodium hydroxide for 
three minutes using a Vortex mixer. After centrifuging for 10 minutes at 1100g 
(RCF), 0.02 ml of the aqueous layer was injeced into the HPLC system. Limit 
of quantification (LOQ; 1 μg/ml) and limit of detection (LOD; 0.1 μg/ml) were 
found to be similar as described by Gwak et al., 2005 (Gwak et al., 2005). 
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4.2.16. Pharmacokinetic and statistical analysis (I, II, III) 
Analysis of pharmacokinetic data was carried out using a non-compartmental 
method. The area under the plasma concentration versus time curve (AUC0–12) 
was calculated by the linear trapezoidal rule. The maximum plasma drug 
concentration (Cmax) and the time at maximum concentration (tmax) were directly 
determined from individual plasma concentrations-versus-time curves. The 
half-life (t1/2), hybrid constant volume of distribution/bioavailability parameter 
(Vd/F) and hybride constant clearence/bioavailability fraction (Cl/F) were cal-
culated as described by Bauer et. al (Bauer, 2008). Statistical analysis of phar-
macokinetic data was carried out using unpaired t-tests. Differences between 
pharmacokinetic parameters of study groups were considered as statistically 
significant if the p-value was less than 0.05. 
PCA and MCR-ALS multivariate analysis methods were used to analyze the 
Raman spectra collected during the storage stability study. The spectral range 
from 1073 cm–1 to 1661 cm–1 was used for data analysis. PCA was carried out 
with Simca-P+ ® software (Version 12.0.1, Umetrics AB, Umea, Sweeden). The 
MCR-ALS was carried out with Unscrambler X® (Version 10.3, Camo soft-
ware, Oslo, Norway). The Raman spectra were preprocessed using standard 
normal variate (SNV) correction. A linear baseline correction and baseline 
offset were also employed in order to minimize the effect of fluorecence on the 
multivariate data analysis. For MCR-ALS, pure Raman spectra of SD, PM AH 
and PM MH were used for initial estimates. Non-negativity of component 
concentrations and closure were applied as constraints. The R2X(cum) and 
Q2(cum) values were used to evaluate the PCA model. The R2X (cum) is a 
measure of explained overall variance of the data and it shows how well the 
data is explained by model. The Q2(cum) indicates how well the model predicts 
new data based on internal cross-validation. The MCR-ALS model performance 
was tested by comparing it to the PCA model. Since PCA provides the best 
possible fit along a set of orthogonal principal components (PCs), a similar 
number of PCs needed and also the similarity between the total variation 
described by the PCA and MCR-ALS show that the MCR-ALS model is 
performing reasonably well in terms of fit. 
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Figure 4. X-ray powder diffraction (XRPD) patterns of piroxicam anhydrate I (AH), 
piroxicam monohydrate (MH), physical mixture of AH and Soluplus® 1:4 (PM), and 
solid dispersion of AH and Soluplus® 1:4 (SD). Theoretical patterns of AH and MH are 
shown for comparison. 
 
5.1.2. Raman spectroscopy (I, II, III) 
Different solid-state forms of PRX exhibited differences in Raman spectra, and 
enabled their identification (Fig. 5). In addition, the Raman spectra of different 
PRX forms were in good agreement with the previously published Raman spectra 
of AH and MH (Kogermann et al., 2007a; Kogermann et al., 2011; Kogermann 
et al., 2007b). There were only minor differences in peak positions, probably 
due to variation between the equipment used. AH showed characteristic peaks 
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5. RESULTS AND DISCUSSION 
5.1. Solid state characterization (I, II, III) 
The formation of PRX solid state forms (AH, MH and amorphous SD) was 
verified by means of XRPD, Raman spectroscopy, FTIR-ATR and DSC. 
 
5.1.1. XRPD (I, III) 
XRPD patterns of solid state forms were in good agreement with the calculated 
theoretical patterns obtained from CSD and previously published diffraction 
patterns of PRX solid state forms (Kogermann et al., 2011).The XRPD pattern 
of PM showed peak positions identical to those of AH (Soluplus® as an 
amorphous polymer showed no peaks). The XRPD pattern of SD showed a 
characteristic halo thus verifying the presence of amorphous PRX (Fig. 4). 
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at 1235 cm–1, 1279 cm–1, 1334 cm–1, 1433 cm–1 and 1522 cm–1. As expected, 
peak positions in Raman spectrum of PM AH were identical to the peak 
positions of pure AH. The intensities of the peaks measured in PM AH were 
lower than in case of AH. Since the intensities of characteristic Soluplus® peaks 
were very low compared to the intensities of PRX peaks, the overall 
contribution of them to the Raman spectra of PM AH was almost non-existent. 
MH showed five characteristic peaks in a range of 1128 cm–1 – 1238 cm–1. In 
addition, two higher peaks at 1401 cm–1 and 1463 cm–1 characteristic to MH 
were observed. Raman spectum of SD showed broader peaks (Fig. 5) being 
characteristic to the amorphous state (Bernstein, 2007). For example, the peaks 
seen at 1334 cm–1 and 1235 cm–1 were broader compared to AH. There were 
also some shifts in the peak positions of SD compared to AH and PM AH which 
is characteristic to the amorphous form (Kogermann et al., 2011). For example, 
the AH peaks at 1151 cm–1, 1433 cm–1 1473 cm–1 and 1558 cm–1 shifted to 
1154 cm–1, 1435 cm–1 1476 cm–1 and 1561 cm–1, respectively. In addition, the 
relative intensity of the peak at 1334 cm–1 in SD spectrum was considerably 
decreased compared to that observed in AH and PM AH spectra. Peak 
broadening and shifts in SD spectrum provide evidence that hydrogen bonding 
interactions between the polymer and PRX are present. 
 
 
Figure 5. SNV corrected Raman spectra of piroxicam (PRX) solid-state forms measured 
immediately after preparation. Amorphous solid dispersion (SD) of PRX and Soluplus® 
graft co-polymer 1:4 (SD), physical mixture of PRX anhydrate form I (AH) and Soluplus® 
1:4 (PM AH), PRX anhydrate form I (AH), physical mixture of PRX monohydrate (MH) 
and Soluplus® 1:4 (PM MH) and PRX monohydrate (MH). Characteristic peaks for 
amorphous PRX in SD are marked with dashes (––), for AH with dots (···) and for MH 
with dashes and dots (?···), respectively. All spectra are offset for clarity. 
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5.1.3. ATR-FTIR (I, II) 
As seen in Figure 6, there are clear differences between the ATR-FTIR spectra 
of SD and corresponding physical mixtures (PM AH). The major difference 
between the spectra of PM AH and SD is the widening of the PRX N-H 
stretching vibration band in the SD spectrum (located at 3337 cm–1 in the PM 
AH spectrum). Several previous studies on the SDs of PRX and polyvinyl-
pyrrolidone (PVP) have reported the widening of the PRX NH stretching 
vibration band in the region of the spectrum from 3000 cm–1 to 4000 cm–1 as a 
proof of hydrogen bonding between PRX and PVP in SDs (Banchero et al., 
2009; Tantishaiyakul et al., 1999). It is evident that the hydrogen bonding 
between the NH group of PRX molecule and the >N– or C=O group of PVP 
might be strong enough to weaken the NH stretching of PRX resulting in a very 
weak and wide peak (Tantishaiyakul et al., 1999). Similarly to Tantishaiyakul et 
al. and Banchero et al. studies, vibrational band at 3337 cm–1 in the ATR- FTIR 
spectrum of SD has become widened. As the molecule of Soluplus® also 
possesses >N- and C=O functional groups, it is evident that hydrogen bonding 
is taking place between the present graft copolymer and PRX in SDs. The 
Raman spectrum of PM MH shows several specific vibrational bands in the 
spectral region from 3000 cm-1 to 4000 cm-1, which makes it easier to 
distinguish from the spectra of SD and PM AH. 
 
 
Figure 6. ATR-FTIR spectra of piroxicam (PRX) solid-state forms measured 
immediately after preparation. Amorphous solid dispersion of PRX and Soluplus® graft 
copolymer 1:4 (SD), physical mixture of PRX anhydrate form I (AH) and Soluplus® 1:4 
(PM AH), PRX anhydrate form I (AH), physical mixture of PRX monohydrate (MH) 
and Soluplus® 1:4 (PM MH), and PRX monohydrate (MH). The arrows indicate the N-
H stretching vibration band of PRX at 3337 cm–1. All spectra are offset for clarity. 
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5.1.4. DSC (I) 
DSC results verified the purity of AH and MH, and showed the thermal events 
(melting and dehydration endotherms) at expected temperature ranges (Fig. 7). 
 
 
  
Figure 7. DSC thermograms of piroxicam anhydrate I (AH), piroxicam monohydrate 
(MH), physical mixture of AH and Soluplus® 1:4 (PM AH), and solid dispersion of AH 
and Soluplus® 1:4 (SD) and pure Soluplus®. 
 
AH melting endotherm onset was observed at 199 ºC. Dehydration endotherm 
of MH was observed between 90 ºC and 149 ºC, and the subsequent melting 
endotherm onset of AH was recorded at 199 ºC. These results were in accordance 
with the previously reported values (Kogermann et al., 2007a; Vre?er et al., 
2003), Soluplus® and PM AH showed a wide endotherm between 35 ºC and 
110 ºC, which could be attributed to the removal of water absorbed by the 
polymeric excipient. In the thermogram of amorphous SD this endotherm was 
narrower, from 35 ºC to 90 ºC. This difference can be attributed to the increased 
temperature used to prepare SD, which can induce the removal of water. PM 
AH showed also another wide endotherm between 125 ºC and 185 ºC, which 
can be attributed to the fusion of PRX. The depression of fusion temperature of 
PRX in PM AH compared to the melting temperature of pure AH can be 
attributed to the interaction with Soluplus®. This kind of behavior is quite usual 
for systems composing of crystals of small organic drug molecules and 
amorphous polymeric excipients (Marsac et al., 2006; Zhao et al., 2011). 
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Figure 8. Dissolution of piroxicam (PRX) solid-state forms from hard gelatin capsules 
(size 3) in hydrochloric acid buffer (pH 1.2) at 37 °C (data are exhibited as mean 
(n=5)±S.E). Key: Piroxicam anhydrate I (AH), piroxicam monohydrate (MH), physical 
mixture of AH and Soluplus® 1:4 (PM AH), and solid dispersion of AH and Soluplus® 
1:4 (SD). 
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5.2. Physical solid state stability in aqueous  
media during dissolution testing (I, II, III) 
5.2.1. Dissolution testing (I, II, III) 
Significant differences were found in the rate and extent of in vitro dissolution 
of different PRX solid-state forms from capsules (Fig. 8). SD showed the 
highest dissolution rate compared to those obtained with the other samples (Fig. 
8). The lowest rate of dissolution was observed with MH, which is the most 
stable form of PRX in aqueous conditions, and therefore it is the least soluble 
(Fig. 8). AH exists in the form of dimers, where two PRX molecules are joined 
together with two intermolecular hydrogen bonds (Vre?er et al., 2003). In AH, 
PRX molecules are neutral with an EZE conformation. MH exists in the form of 
two hydrogen bonded PRX dimers that are connected by a central tetramer that 
consists of four water molecules joined together by hydrogen bonds. Therefore, 
PRX molecules in MH are in a zwitterionic form with a ZZZ conformation. 
Water molecules in MH structure stabilize the zwitterionic PRX molecules and 
thus lower the free energy of MH relative to AH (Sheth et al., 2004c). The 
lower solubility of MH compared to AH has previously been reported (Paaver 
et al., 2012). 
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In SD, PRX exists in an amorphous form, and consequently, dissolution does 
not need to overcome the energy barrier for breaking up the crystal lattice. In 
addition, amorphous SDs are known to generate high or even supersaturated 
concentrations of poorly soluble drugs by increasing their apparent solubility 
and dissolution rate (Brouwers et al., 2009). An amorphous solid may have 
some short-range molecular order and there could be a relationship between the 
neighboring molecules but there is no long-range order in their molecular 
packing (Yu, 2001). The lack of long range order in the molecular packing and 
thus lack of crystallinity results in higher free energy compared to the 
crystalline counterparts (Hancock and Zografi, 1997). 
Additional experiment with PM AH was performed to investigate the effect 
of excipient (Soluplus®) on the dissolution behavior of PRX. Furthermore, it 
was hypothesized that an increase in the dissolution rate of PRX from SD 
(compared to AH) was due to PRX being amorphous, and not only by the 
solubilizing properties of Soluplus® (Fig. 8). The results suggest that the total 
amount of dissolved PRX was increased both with SD and PM AH compared to 
AH and MH. As seen in Figure 8, the release profile of PRX from PM AH was 
almost linear (zero-order kinetics). According to the literature, Soluplus® with 
an amphiphilic chemical structure has an excellent affinity to form a molecular 
dispersion with drugs which makes it a good solubilizer for poorly water-
soluble drugs (Thakral et al., 2011). The Raman spectroscopy results showed 
that Soluplus® also prevents the water-mediated phase transformation of AH to 
MH in both PM AHs and SDs (this is described more precisely in the paragraph 
“Slurry Tests”). The present results are in accordance with previous studies 
reporting the dissolution of amorphous SDs containing PVP as a hydrophilic 
polymer (Tantishaiyakul et al., 1999). 
Additional test was carried out with powders of PRX solid state forms 
introduced directly to the dissolution medium in order to detect the possible 
effect of capsule shell on the dissolution. Although the general trends were 
similar, also the formulation of drug (capsule vs. powder) turned out to be 
important (Figs. 8 and 9). As can be seen the SD introduced to dissolution 
medium as powders released all the PRX within 10 minutes while from 
capsules only 45% was relesed. Also the release of PRX from PM AH was 
significantly faster from powders. The slower release rate of PRX from 
amorphous SD in capsules was probably due to the effect of the capsule shell. 
This hinders the disintegration process of the SD which causes the formation of 
supersaturated PRX solution between the particles, leading to the partial 
crystallization of PRX as MH. 
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Figure 9. Dissolution profiles of piroxicam (PRX) solid state forms (as powders) in 
900 ml of hydrochloric acid buffer (pH 1.2) at 37 °C (n = 3). Average standard error 
was ±0.49% and is not shown for clearance purposes. Key: Solid dispersion of PRX and 
Soluplus® graft co-polymer 1:4 (SD), physical mixture of PRX anhydrate I (AH) and 
Soluplus® 1:4 (PM AH), physical mixture of PRX monohydrate (MH) and Soluplus® 
1:4 (PM MH). 
 
5.2.2. Intrinsic dissolution test (I) 
To get further insight into the solubility of different solid-state forms, intrinsic 
dissolution tests were performed (Fig. 10). As observed in the dissolution test 
with basket method, SD showed the highest intrinsic dissolution rate within the 
first 15 minutes (61.6 μg/min/cm2) after which a gradual decrease in IDR was 
determined up to 60 minutes sampling point. In the last phase of the test the 
intrinsic dissolution rate of SD was similar to MH (10.7 μg/min/cm2). This is 
due to the conversion of amorphous PRX to MH which was confirmed by 
Raman spectroscopy. Such changes in the IDR are typical for APIs that exhibit 
solid-state transformations during dissolution testing (Greco and Bogner, 2011). 
Similar behavior has also been reported for amorphous indometacin and 
carbamazepine during IDR testing (Savolainen et al., 2009).  
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Figure 10. Intrinsic dissolution rate measurement of (PRX) solid-state forms in 
hydrochloric acid buffer (pH 1.2) at 37 °C (n=3). Key: Piroxicam anhydrate I (AH), 
piroxicam monohydrate (MH), physical mixture of AH and Soluplus® 1:4 (PM AH), 
and solid dispersion of PRX and Soluplus® 1:4 (SD). 
 
The second highest IDR was measured with PM (26.2 μg/min/cm2), which was 
quite close to the IDR of AH (24.4 μg/min/cm2). This result, however, is in 
contrast to the results obtained in the dissolution test with basket method and 
this discrepancy is probably due to the rapid dissolution and solubility-
enhancing effect of Soluplus® around PRX in the PM AH and the interaction 
between a polymer and gelatin capsule during dissolution testing with capsules. 
The lowest IDR was measured for MH (12.5 μg/min/cm2). It was expected that 
also the dissolution rate of AH would change during IDR testing, since MH 
formation has been reported to occur during solubility testing (Jinno et al., 
2000) and IDR testing (Tsinman et al., 2009). However, in the time-scale of 
IDR testing performed in the present study (up to 120 minutes), this was not 
observed.  
 
5.2.3. Slurry tests (I) 
Slurry tests together with Raman spectroscopic monitoring were performed in 
order to investigate the solid-state transformations in the dissolution medium. In 
slurry tests AH and SD converted to MH at different rates.  
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Figure 11. a) Piroxicam anhydrate (AH) conversion to piroxicam monohydrate (MH) in 
during slurry test monitored by means of Raman spectroscopy. b) Solid dispersion of 
PRX and Soluplus® 1:4 (SD) conversion to piroxicam monohydrate (MH) during slurry 
test monitored by means of Raman spectroscopy. Raman spectra are shown after 
different time-points during slurry testing (minutes). 
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As seen in Figure 11a, AH converted to MH within 220 minutes of mixing, 
which may explain the decrease in dissolution rate during the dissolution test 
with basket method (see Fig. 8). Amorphous PRX in SDs converted to MH after 
10 minutes of mixing (Fig. 11b). These results are in accordance with previous 
study where amorphous PRX prepared by low temperature milling converted to 
MH in simulated gastric fluid (without pepsine) within few minutes of testing 
(Naelapää et al., 2012). These results were supported by the intrinsic dissolution 
rate measurements as the dissolution rate of SD was decreasing. Surprisingly, 
PM AH did not show any changes in the solid-state form during the slurry test 
within eight hours. This is probably due to the adsorption of amphiphilic 
Soluplus® onto PRX crystals and the formation of stabilizing hydrogen bonds, 
which can inhibit the recrystallization. This kind of recrystallization inhibition 
has also been reported with other polymers and APIs (Murdande et al., 2011). 
Formation of hydrogen bonds between PRX and Soluplus® may also increase 
the activation energy of nucleation (Brouwers et al., 2009). 
 
 
5.3. Physical solid-state stability  
of solid dispersions during storage (II) 
5.3.1. Effects of “low-humidity” storage conditions (II) 
No significant changes in the ATR-FTIR spectrum of SDs were observed 
during a six-month short-term stability study when the samples were stored at 
low humidity and low temperature (~0% RH/ 6 °C) and at low humidity and 
intermediate temperature (~0% RH / 25 °C) conditions (Figs. 12a and 12b).  
Similar results were obtained using Raman spectroscopy. The interpretation 
of Raman spectra collected during the storage of SDs was found to be more 
difficult than the interpretation of the corresponding ATR-FTIR spectra. 
Consequently, Raman spectroscopy was combined with PCA, which enabled 
better visualization and investigation of the possible solid-state transformations 
of PRX during storage (Fig. 13). Three PCs were needed to describe 99.8% of 
the chemically meaningful variation in all Raman spectra. PCA scores and 
loading vector of the first PC (PC 1) explained 97.9% of the variation in Raman 
spectra. The second PC (PC 2) and third PC (PC 3) explained 1.1% and 0.8% of 
the variation, respectively. The loading vector of PC 1 correlated positively to 
the spectrum of SDs, the loading vector of PC 2 correlated negatively to the 
spectrum of PM AH and positively to the spectrum of PM MH, and PC 3 
correlated positively to the spectra of PM AH and PM MH (Fig. 13a and 13b). 
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Figure 12. ATR-FTIR spectra of amorphous solid dispersions of piroxicam (PRX) and 
Soluplus® graft co-polymer 1:4 (SDs) stored at a) ~0% RH / 6 °C, b) ~0% RH / 25 °C, 
Key: The SDs stored for one day (SD 1D), one week (SD 1W), one month (SD 1M) and 
for six months (SD 6M). The respective spectrum of fresh SD (immediately after 
preparation), physical mixture of PRX anhydrate I (AH) and Soluplus® 1:4 (PM AH), 
and physical mixture of PRX monohydrate (MH) and Soluplus® 1:4 (PM MH) are 
shown as references. The arrows indicate the N-H stretching vibration band of PRX at 
3337 cm–1. All spectra are offset for clarity. 
A
bs
or
ba
nc
e 
Wavenumber (cm-1) 
PM MH 
PM AH 
SD  
SD 1D 
SD 1W 
SD 1M 
SD 6M 
a) 
? 
A
bs
or
ba
nc
e 
Wavenumber (cm-1) 
PM MH 
PM AH 
SD 
SD 1D 
SD 1W 
SD 1M 
SD 6M 
b) 
? 
44 
 
 
Figure 13. a) The 3D principal component analysis (PCA) scores plot for the first, second 
and third principal components (PC 1, PC 2 and PC 3, respectively) of solid dispersions 
(SDs) stored in different conditions together with pure forms: SD of piroxicam (PRX) and 
Soluplus® 1:4 (SD, marked with green dot and arrow), physical mixtures of PRX 
anhydrate I (AH) and Soluplus® (PM AH, marked with red dot) and PRX monohydrate 
(MH) and Soluplus® (PM MH, marked with blue dot). Cluster of principal components 
(PCs) of Raman spectra recorded from samples stored at low humidity is surrounded with 
green circle. The red arrow shows the evolution of PCs of Raman spectra recorded at 
intermediate humidity from first day up to six months of storage. The blue arrow shows 
the evolution of PCs of Raman spectra recorded at high humidity from first day up to six 
months of storage. b) Loadings of the PC1, PC2 and PC3. SNV corrected Raman spectra 
of AH PM, SD and MH PM are shown for comparison and all spectra are offset for 
clarity. Characteristic peaks for amorphous PRX in SD are marked with dashes (––), for 
AH with dots (···) and for MH with dashes and dots (?···) respectively. 
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In the 3D PCA scores plot, the dots representing the Raman spectra for the SD 
samples stored at low humidity formed a clear cluster around a dot representing 
the Raman spectrum of SD immediately after preparation (Fig. 13a). This 
indicates that no solid-state transformations had taken place in the SD samples 
stored at low humidity. The results of ATR-FTIR and Raman spectroscopy 
suggest that the SDs of PRX and Soluplus® prepared by a solvent evaporation 
method are physically stable in a powder form in the present storage conditions 
for at least six months. This is an interesting finding since previous studies have 
shown that the corresponding SDs of PRX and Soluplus® prepared by ball-
milling recrystallize within two months (Kogermann et al., 2013). It is evident 
that the use of different methods for preparing SDs can result in different 
molecular arrangements and drug-polymer interactions in the final product. 
Different preparation methods can result in different sizes of nuclei and also the 
degree of mixing of polymer and API can be different. With ball milling, the 
molecular-level dispersion of drug molecules in carrier polymer can be limited 
which means that the physical stability is compromised. 
 
5.3.2. Effects of “intermediate humidity” storage conditions (II) 
The ATR-FTIR spectra of the SD samples stored at intermediate humidity 
conditions showed that PRX recrystallized out as PRX AH (Fig. 14).  
 
 
Figure 14. ATR-FTIR spectra of amorphous solid dispersions of piroxicam (PRX) and 
Soluplus® graft co-polymer 1:4 (SDs) stored at ~40% RH / 25 °C. Key: The SDs stored 
for one day (SD 1D), one week (SD 1W), one month (SD 1M) and for six months (SD 
6M). The respective spectrum SD immediately after preparation, physical mixture of PRX 
anhydrate I (AH) and Soluplus® 1:4 (PM AH), and physical mixture of PRX monohydrate 
(MH) and Soluplus® 1:4 (PM MH) are shown as references. The arrows indicate the N-H 
stretching vibration band of PRX at 3337 cm–1. All spectra are offset for clarity. 
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After four days of storage, the N-H stretching band characteristic to PRX AH 
appeared at 3337 cm–1. Furthermore, there were also other changes of the peaks 
in the fingerprint area that were suggesting increased crystallinity in the SD 
samples. 
Raman spectroscopy combined with multivariate analysis was used to further 
investigate the physical solid-state changes of PRX. PCA and MCR-ALS was 
used to carry out qualitative and quantitative analysis of the Raman spectra (Fig. 
13a, 13b, 15a and 15b). In the PCA plots, the Raman spectra for the SD samples 
stored at intermediate humidity and temperature line up on a vector that points 
from the dot representing the Raman spectra of SDs towards the dot 
representing the Raman spectrum of PM AH (Fig. 13a and 13b). The present 
results confirmed the corresponding results obtained with ATR-FTIR. It can be 
concluded that the present SDs of PRX and Soluplus® are physically unstable 
when stored at higher humidity and temperature, and tend to recrystallize as 
PRX AH already after short-term aging (1 week). This is contrary to the results 
obtained with the SD samples stored at low humidity and low/intermediate 
temperature conditions. 
Raman spectra for the SD samples stored at intermediate humidity and 
temperature conditions were investigated in more detail using MCR-ALS (Fig. 
15a and 15b). This also allows (semi-) quantitative analysis of the physical 
solid-state changes in the aged SDs. Figure 15a shows the MCR-ALS calculated 
amounts of amorphous PRX and crystalline PRX and Figure 15b shows the 
MCR-ALS estimated Raman spectra of the components in the samples stored at 
the intermediate humidity and temperature conditions. Raman spectroscopy 
coupled with MCR-ALS was able to detect and quantify the crystallization of 
PRX already after one day of storage. After six months of storage, 
approximately 40% of PRX had crystallized as AH. The MCR-ALS model for 
Raman spectra collected from the samples stored at 40% RH / 25 °C showed 
that only two PCs existed in a given system and the model described 99% of the 
variation in the given data matrix. The present results were in good agreement 
with the PCA model for the Raman spectra obtained from the aged SD samples 
stored at 40% RH / 25 °C. In this model, two PCs described 99.6% of the total 
variation in the data (data not shown). As PCA provides the best possible fit 
along a set of orthogonal PCs, the similarity of the number of PCs needed and 
the similarity between the total variation (described by the PCA and MCR-
ALS) provide evidence that the MCR-ALS model is also performing reasonably 
well in terms of fit. 
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Figure 15. a) Multivariate curve resolution alternating least squares (MCR-ALS) 
estimated concentrations of piroxicam (PRX) solid state forms in amorphous solid 
dispersion (SD) samples stored at ~40% RH/25 °C. b) MCR-ALS estimated Raman 
spectra of pure components encountered in the samples stored at ~40% RH/25 °C. 
Legend: Solid dispersion of PRX and Soluplus® 1:4 (SD), physical mixture of PRX 
anhydrate I (AH) and Soluplus® (PM AH) and physical mixture of PRX monohydrate 
(MH) and Soluplus® (PM MH). The Raman spectra of PRX solid state forms are shown 
for comparison and all spectra are offset for clarity. Characteristic peaks for amorphous 
PRX in SD are marked with dashes (––), for AH are marked with dots (···) and for MH 
are marked with dashes and dots ( ?···) respectively. 
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5.3.3. Effects of “high humidity” storage conditions (II) 
At higher humidity and intermediate temperature conditions (~75% RH / 
25 °C), clear signs of premature crystallization of PRX in SDs as AH was 
observed after a short-term aging period (Fig. 16). The characteristic NH 
stretching vibration band of PRX AH in the ATR-FTIR spectrum was displayed 
at 3337 cm–1 already after one day storage (Fig. 16).  
 
 
Figure 16. ATR-FTIR spectra of amorphous solid dispersions of piroxicam (PRX) and 
Soluplus® 1:4 (SDs) stored at ~75% RH / 25 °C. Key: The SDs stored for one day (SD 
1D), one week (SD 1W), one month (SD 1M) and for six months (SD 6M). The 
respective spectrum of SD immediately after preparation, physical mixture of PRX 
anhydrate I (AH) and Soluplus® 1:4 (PM AH), and physical mixture of PRX 
monohydrate (MH) and Soluplus® 1:4 (PM MH) are shown as references. The arrows 
indicate the N-H stretching vibration band of PRX at 3337 cm–1. All spectra are offset 
for clarity. 
 
In the PCA plots, the Raman spectra for the aged SD samples (stored at high 
humidity-intermediate temperature conditions for one month) line up on a 
vector that points from the dot representing the Raman spectrum of SD towards 
the dot representing the Raman spectrum of PM AH (Figs. 13a). This suggests 
that after one month’s storage most of the amorphous PRX had recrystallized as 
AH. The dots representing the Raman spectra for the SD samples stored at high 
humidity-intermediate temperature conditions for longer than one month line up 
on a vector that points from the dot representing the Raman spectrum of AH 
towards the dot that represents the Raman spectrum of PM MH (Figs. 13a). The 
present results indicated that even one month’s storage at high humidity and 
intermediate temperature caused AH to recrystallize as MH. 
A
bs
or
ba
nc
e 
Wavenumber (cm-1) 
PM MH 
PM AH 
SD 
SD 1D 
SD 1W 
SD 1M 
SD 6M 
? 
? 
? 
? 
? 
49 
Figure 17. a) Multivariate curve resolution alternating least squares (MCR-ALS) 
calculated concentrations of PRX solid state forms in SD stored at ~75% RH/25 °C and 
b) MCR-ALS estimated Raman spectra of pure components encountered in the samples 
stored at ~75% RH/25 °C. Legend: Solid dispersion of PRX and Soluplus® 1:4 (SD), 
physical mixture of PRX anhydrate I (AH) and Soluplus® (PM AH) and physical 
mixture of PRX monohydrate (MH) and Soluplus® (PM MH). The Raman spectra of 
PRX solid state forms are shown for comparison and all spectra are offset for clarity. 
Characteristic peaks for amorphous PRX in SD are marked with dashes (––), for AH are 
marked with dots (···) and for MH are marked with dashes and dots ( ?···) respectively. 
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Raman spectroscopy combined with MCR-ALS confirmed the results obtained 
with ATR-FTIR and Raman spectroscopy together with PCA (Figs 17a and 
17b). During a short-term storage for one day and one month, approximately 
20% and 80% of PRX crystallized as AH, respectively. The recrystallization as 
PRX MH was detected after one month storage and after six months storage the 
amount of MH increased up to approximately 20%. The amount of PRX AH 
started to decrease after three months storage and this suggests that not only 
amorphous PRX is crystallizing as MH but also PRX AH recrystallizes as MH 
(Fig. 17a). The comparison of MCR-ALS and PCA models for Raman spectra 
obtained with the SD samples stored at ~75% RH / 25 °C verified that the 
MCR-ALS was preforming reasonably well in terms of fit. The PCA model for 
the Raman spectra of the corresponding aged SD samples used three PCs for 
describing 99.9% of the total variation in the data (data not shown). The MCR-
ALS also needed three components to describe 97.6% of the total variation in 
the data. 
 
5.3.4. Comparison of different storage conditions (II) 
The present SDs were physically stable in a powder form at ~0% RH / 6 °C (“low 
humidity-low temperature”) and ~0% / 25 °C (“low humidity-intermediate 
temperature”) for at least six months. These SDs, however, are physically 
unstable at higher humidity conditions (~40% RH / 25 °C and ~75% RH / 25 °C) 
since amorphous PRX crystallizes out firstly as a AH and subsequently as MH 
within 2–3 months. It is evident that the absorbed water acts as a plasticizer in 
the SDs and thus increases the molecular mobility of amorphous PRX leading 
to premature crystallization. Hydrogen bonding between PRX and a carrier 
polymer (Soluplus®) is not strong enough to stabilize PRX in amorphous form 
at higher humidity conditions. Recrystallization as MH under 75% RH 
conditions probably does not occur via AH in the bulk material since AH has to 
be dissolved in order to allow this to take place as AH and MH have completely 
different unit cell structures (Kojic-Prodic and Ruzic-Toros, 1982; Reck et al., 
1988; Reck and Laban, 1990). As the amount of condensed water is higher on 
the surface of powder particles, it is evident that there is enough free water 
available to dissolve not only amorphous PRX but also crystalline PRX. This is 
obviously one reason, why the decrease in intensity of characteristic AH N-H 
stretching band (in the aged SD samples – ATR-FTIR spectra) was observed 
only with the SD samples stored at ~75% RH / 25 °C (Fig. 16). 
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5.3.5. Dissolution behavior of stored piroxicam  
solid dispersions (II) 
The dissolution profile of PRX obtained with the SDs exposed to different 
humidity and temperature storage conditions depended on the crystallization of 
PRX during the stability study (Fig. 18a, 18b and 18c). In addition, the amount 
of PRX converted to the crystalline state during storage and the crystal form 
itself were also important factors affecting the dissolution. This is in agreement 
with the earlier findings on the dissolution behavior of recrystallized amorphous 
SDs prepared with Soluplus® and cinnarizine (Tian et al., 2014). After one 
week’s storage, only the SD samples stored at high humidity and intermediate 
temperature conditions showed decreased dissolution rate (Fig. 18a). After one 
month’s storage, the SD samples stored at intermediate humidity and tem-
perature conditions also exhibited a slightly decreased PRX dissolution rate 
compared to that obtained with the fresh SDs immediately after preparation 
(Fig. 18b). After six months’ storage, the SD samples stored at intermediate 
humidity and temperature and high humidity and intermediate temperature 
showed markedly decreased dissolution rate, while the samples stored under 
low humidity conditions displayed similar characteristics to the fresh SDs (Fig. 
18c). The present dissolution results are in line with the ATR-FTIR and Raman 
spectroscopy analyses of solid-state changes of PRX in the SDs during a short-
term storage. 
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Figure 18. a) Dissolution profiles of the PRX solid dispersions (SDs)(as powders), 
stored at different conditions for one week, in 900 ml of hydrochloric acid buffer (pH 
1.2) at 37 °C (n = 3). Average standard error was ±0.62% and is not shown for 
clearance purposes. b) Dissolution profiles of the PRX solid dispersions (SDs)(as 
powders) stored at different conditions for one month in 900 ml of hydrochloric acid 
buffer (pH 1.2) at 37 °C (n = 3). Average standard error was ±0.39% and is not shown 
for clearance purposes. c) Dissolution profiles of the PRX solid dispersions (SDs)(as 
powders) stored at different conditions for six months in 900 ml of hydrochloric acid 
buffer (pH 1.2) at 37 °C (n = 3). Average standard error was ±0.79% and is not shown 
for clearance purposes. 
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5.4. Physical solid state stability of piroxicam during 
processing (III) 
5.4.1. Solid-state transformations of piroxicam  
in aqueous drug-layer coating (III) 
Raman spectroscopy enabled to identify the solid-state forms of PRX also 
during and after drug-layer coating of pellets (Figs. 19a, 19b and 19c). 
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Figure 19 
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Figure 19. Raman spectra of neutral pellets drug-layer coated with (a) PRX anhydrate 
form I (AH), (b) PRX monohydrate (MH), (c) amorphous PRX as a solid dispersion 
(SD) of PRX and Soluplus® 1:4. Multiple Raman spectra were taken at 10, 20, 30 and 
60 minutes. Raman spectra of microcrystalline cellulose (MCC); hydroxypropyl 
methylcellulose (HPMC); Soluplus®, amorphous PRX as a solid dispersion (SD) of 
PRX and Soluplus® 1:4, PRX anhydrate form I (AH) and PRX monohydrate (MH) are 
shown for comparison. All spectra are normalized and off-set for clarity. Arrows point 
to characteristic Raman peaks of AH, MH and SD. 
 
Aqueous-based drug-layer coating of pellets has been widely used for manu-
facturing controlled drug release multiple-unit systems for e.g. oral pulsatile 
and/or sustained-release applications (Ensslin et al., 2009; Heinicke and 
Schwartz, 2004; Möschwitzer and Müller, 2006; Rahman et al., 2006; Sin-
chaipanid et al., 2004; Tian et al., 2008). The manufacturing in a fluid-bed or air-
suspension process involves application of drug-polymer mixture coating layers 
on the pellet cores using a spray-atomization technique, and subsequent drying 
of the coated solids. As given process involves elevated temperature and 
suspending of the agent beeing coated in liquid it is vital to monitor the solid 
state form during coating. 
Excipients, HPMC and MCC, did not interfere with the detection of PRX 
forms since their Raman peak intensity was quite low compared to PRX ones 
(Figs. 19a, 19b and 19c). The results of Raman spectroscopy revealed that 
different solid-state forms of PRX behaved differently during the drug-layer 
coating of pellets (Figs. 19a, 19b and 19c). AH and MH were found to be more 
stable forms than SD in aqueous-based drug-layer coating. The amorphous PRX 
(SD) was unstable and its crystallization as MH was identified with Raman 
spectroscopy already after 10 minutes of drug-layer coating of pellets (Fig. 
19c). The results showed that AH and MH did not transform to any other solid 
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state form within a 1-hour aqueous drug-layer coating of pellets (Figs. 19a and 
19b), thus revealing that AH and MH were stable in aqueous HPMC solution 
and during coating. In previous studies, AH has been shown to undergo 
transformation to MH during solubility testing (Jinno et al., 2000) and 
dissolution (Naelapää et al., 2012) measurements. The hydrate formation of 
PRX in pure distilled water has been reported to occur within 55 minutes in 
slurry testing (Paaver et al., 2012). In the present study, probably the presence 
of HPMC inhibited or slowed down the solid-state transformation from AH to 
MH. As expected, MH remained unchanged since MH is the most stable form 
of PRX in aqueous conditions (Sheth et al., 2004c). 
 
5.4.2. Drug-layer coating efficiency (III) 
Good correlations were obtained between the drug-layer coating time (10, 20, 
30 and 60 minutes) and Raman peak intensity of AH (Fig. 19a) and MH (Fig. 
19b). The characteristic PRX peaks in Raman spectrum were much less visible 
during the first phases of coating (10, 20 and 30 minutes) with SD because the 
percentage of PRX by weight in SD coating suspension was lower (Fig. 19c). 
However, Raman spectroscopy can be used to draw conclusions about the drug-
layer coating efficiency. The longer coating time resulted in the higher intensity 
of the characteristic PRX peaks and therefore better coating efficiency. Similar 
results have been obtained by Wirges et al during coating of the tablets (Wirges 
et al., 2013). The improved coating efficiency was also verified by the weight 
gain of pellets during coating experiments (Table 1), and from SEM micro-
graphs (Figs. 20a, 20b and 20c). As can be seen from Table 1, the percentage 
weight increase (%) in drug-layer coated neutral pellets (vs uncoated pellets) 
was quite similar for pellets coated with AH and for pellets coated with MH 
(SD values are not shown due to different testing conditions). Moreover, longer 
coating time resulted in higher coating efficiency (%) (Table 1). In addition, 
SEM micrographs revealed the change of pellets surface to more homogeneous 
together with longer coating time thus without any change in pellet surface 
morphology. 
Plasticizers are most commonly used in coating solutions for improving the 
film formation and the mechanical properties of the film coat. Plasticizers are 
known to alter polymer chain interactions and make the hard and brittle coatings 
more flexible and rubber-like (Billmeyer, 1971). According to the literature, 
some drugs (e.g. ibuprofen) can have a significant solid-state plasticization 
effect on pharmaceutical film coatings (Wu and McGinity, 2001). In the present 
study, no external plasticizer was used in the drug-layer coatings. It is 
interesting to note, that different PRX solid-state forms itself showed different 
plasticizing properties. When AH and MH were used, both forms together with 
HPMC allowed to produce easily removable coatings on the coating chamber 
walls and pellets revealed more smooth surfaces. 
Figure 20. Scanning electron micrographs (SEM) of neutral pellets drug-layer coated 
with (a) PRX anhydrate form I (AH), (b) PRX monohydrate (MH) and (c) amorphous 
PRX as a solid dispersion (SD) of PRX and Soluplus® 1:4. From left to right: uncoated 
neutral pellet, and neutral pellets upon coating after specified time-points (minutes). 
Upper row: single pellet (magnification 75×). Bottom row: the surface of a single pellet 
(175×). 
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Surprisingly, SD did not show this kind of property obviously due to the 
addition of Soluplus®, which seemed to have quite cohesive properties in water 
solutions and poor plasticizing characteristics. Furthermore, the SD drug-layer 
coated pellets showed more rough surface compared to the pellets coated with 
AH or MH (Figs. 20a, 20b and 20c). It is evident that during drug-layer coating 
of pellets with SD, an uncontrolled crystallization of MH occurs onto the 
surface of pellets, and this MH probably has totally different crystal properties 
(such as morphology) compared to MH prepared by specified recrystallization 
procedure. The aqueous HPMC coating solution which contained crystallized 
MH had most likely different density and viscosity, and this resulted in different 
coating adhesion, porosity, uniformity and thickness. In addition, other factors 
such as sticking of the pellets to each other and onto the coating chamber wall 
may cause coating surface roughness variation during fluidization coating. 
According to the literature, the mechanical stress developed during a coating 
process and gravitational forces may cause coating non-uniformity (thickness 
uniformity) on different sides of the pellets (Haddish-Berhane et al., 2006). 
 
Table 1. The theoretical percentage weight increase (%), the weight increase (%) in 
drug-layer coated neutral pellets (vs uncoated pellets) and coating efficiency (%) of 
pellets during drug-layer coating of pellets at different time points. The neutral pellets 
are drug-layer coated with different solid-state forms of piroxicam (PRX): PRX 
anhydrate form I (AH), PRX monohydrate (MH). Amorphous PRX (SD) values are not 
shown due to different testing conditions. 
Coating 
time (min) 
Theoretical 
weight 
increase (%) 
AH weight 
increase (%)
AH coating 
efficiency 
(%) 
MH weight 
increase (%)
MH coating 
efficiency 
(%) 
10 2.6 0.9 35.3 1.1 44.2 
20 5.2 3.4 65.6 4.5 87.5 
30 7.7 7.9 102.4 6.3 81.9 
60 15.4 14.2 93.2 12.8 83.4 
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5.4.3. Solid-state transformations of piroxicam in free films (III) 
Raman spectroscopy enabled monitoring different PRX solid-state forms and 
the amount of AH and/or MH also in free films (Figs. 21a, 21b and 21c). 
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Figure 21. Raman spectra of (a) PRX anhydrate form I (AH) free films; (b) PRX 
monohydrate (MH) free films; (c) amorphous PRX as a solid dispersion (SD) of PRX 
and Soluplus® 1:4 free films during drying after specified time-periods (minutes). 
Raman spectra of hydroxypropyl methylcellulose (HPMC), PRX anhydrate form I 
(AH), PRX monohydrate (MH) and Soluplus® are shown for comparison. Arrows point 
to characteristic Raman peaks of AH, MH and SD. 
 
The vibrational spectroscopy results obtained by monitoring the drying stage of 
drug-loaded free films verified those results achieved in a drug-layer coating 
process of the pellets. It was found that in both cases AH and MH remained 
stable during a drying stage and that amorphous PRX (SD) crystallized out as 
MH within the first minutes of drying (Figs 21a, 21b and 21c). As water 
vaporized during the drying of free films, the relative amount of PRX increased 
in free films and this can be seen in the increased intensity of Raman signal and 
reduction of noise (Figs. 21a, 21b and 21c). 
 
5.4.4. Thermal properties of the drug-layer coatings and  
free films (III) 
DSC was used to understand the interaction between the solid-state forms of 
PRX and HPMC, and to verify the solid-state transformations during drug-layer 
coating and in free films. As seen in Figure 22, pure PRX solid-state forms, 
Soluplus® and HPMC show characteristic thermal behavior.  
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Figure 22. Differential scanning calorimetry (DSC) thermograms of Soluplus®, 
hydroxypropyl methylcellulose (HPMC), PRX anhydrate form I (AH) and PRX 
monohydrate (MH). Key: amorphous solid dispersion of PRX and Soluplus® 1:4 (SD), 
PRX anhydrate form I (AH), and PRX monohydrate (MH), dehydration endotherm of 
polymer (I), dehydration endotherm of MH (II), fusion endotherm of AH (III): 
 
The melting temperature of AH and dehydration temperature of MH are in good 
agreement with the respective temperature values reported in the literature 
(Kogermann et al., 2007a; Kogermann et al., 2011; Vre?er et al., 2003). SD did 
not show any glass transition temperature (Tg), but this was obviously due to an 
overlap with the water desorption endotherm as described previously. Similarly, 
the DSC thermogram of pure HPMC carrier polymer showed only dehydration 
endotherm and did not reveal any Tg for the polymer. According to McPhillips 
et al. (1999), the conventional DSC is not able to detect the characteristic Tg for 
HPMC, but a modulated-temperature DSC shows the Tg at approximately 
162 ºC (McPhillips et al., 1999). 
The DSC thermograms of AH and MH layer coatings collected from the 
specific site of a coating chamber wall at different timepoints (30 and 60 
minutes) showed coating time independent characteristics (Fig. 23). 
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Figure 23. Differential scanning calorimetry (DSC) thermograms of drug-loaded 
coatings with piroxicam (PRX) solid state forms taken after specific time periods upon 
coating (minutes). Key: amorphous PRX as a solid dispersion (SD) of PRX and 
Soluplus® 1:4, PRX anhydrate form I (AH), and PRX monohydrate (MH), dehydration 
endotherm of polymer (I), dehydration endotherm of MH (II), fusion endotherm of AH 
(III). 
 
This is quite expected result as no solid state transformation was observed and 
also the precentage (w/w) of AH or MH in dried coatings is expected to remain 
constant throughout the coating process. The melting endotherm of AH coating 
after 30 and 60 minutes of coating was at 190 °C and 191 °C, respectively. The 
decrease in melting temperature compared to the melting temperature of pure 
AH could be attributed to the specific interaction of polymer and drug 
molecules. In addition, both thermograms displayed a broad endotherm ranging 
from 30 to 90 °C which was attributed to the water desorption from HPMC. 
Both thermograms of MH displayed very broad endotherms at a range of 
90?142 °C attributed to the dehydration of MH and the subsequent melting 
endotherm of AH at 189 °C. DSC thermogram of SD showed similar thermal 
behavior as for pure HPMC and Soluplus®.  
The DSC thermograms taken from dry drug-loaded free films showed 
similar characteristics to those taken from drug-layer coatings (Fig. 24). The 
fusion endotherms of polymer and PRX occured at slightly higher temperatures 
at 197 °C for AH and MH compared to the samples taken from a coating 
chamber. This discrepancy can be attributed to Tween 40 which was most likely 
present in the samples taken from a coating chamber.  
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Figure 24. Differential scanning calorimetry (DSC) thermograms of drug-loaded free 
films with piroxicam (PRX) solid state forms taken after specified time-periods upon 
drying (minutes). Key: amorphous PRX as a solid dispersion (SD) of PRX and Soluplus® 
1:4, PRX anhydrate form I (AH), and PRX monohydrate (MH), dehydration endotherm of 
polymer (I), dehydration endotherm of MH (II), fusion endotherm of AH (III) 
 
5.4.5. Dissolution of pellets coated  
with different solid-state forms of piroxicam (III) 
Formulated drug-layer coated pellets of PRX showed clearly faster dissolution 
compared to the powder and powders in a capsule forms (Figs. 8, 9 and 25). 
The pellets coated with AH showed almost the highest dissolution rate (Fig. 
25). Only SD introduced into dissolution medium as powder showed comparably 
fast rate (Fig. 9). The lowest dissolution rate was observed with the pellets coated 
with SD which was obviously due to the formation of MH during an aqueous 
drug-layer coating. Since the amount of coating polymer (HPMC) and 
Soluplus® in SD drug-layer coatings was quite high (compared to the amount of 
PRX), it is also possible that the dissolution of MH can become dependent on 
the diffusion rate of water molecules into the polymer and also to the diffusion 
of the dissolved drug molecules out of the polymer. Similarly Duki?-Ott et al. 
2008 have shown that if PRX is loaded into pellet cores, the diffusion controlled 
drug release can be negligible due to the surrounding enteric coating (Duki?-Ott 
et al., 2008). The pellets coated with MH were not dissolved within the testing 
time of 2 hours (the plateau was not reached in the dissolution curve; Fig. 25). 
Comparison of the dissolution profiles of the drug-layer coated pellets for 15 
minutes vs 1 hour revealed that prolonged coating increased the amount of PRX 
on the surface of the pellets (Fig. 25). Hence, the coating efficiency was 
improved with the longer coating time, and this is in agreement with previous 
studies with pellets coated in a fluid-bed process (Lee et al., 2011).  
30 50 70 90 110 130 150 170 190 210
H
ea
t F
lo
w
 (E
nd
o 
up
) 
Temperature (Co) 
MH  
AH 
SD 
I 
I 
I 
II 
III 
III 
63 
Figure 25. Dissolution profiles of drug-loaded pellets coated with different solid state 
forms of piroxicam (PRX) in hydrochloric acid buffer (pH 1.2). Key: pellets coated with 
amorphous solid dispersion (SD) for 30 minutes (SD 30 min), pellets coated with 
monohydrate (MH) for 15 minutes (MH 15 min), pellets coated with anhydrate form I 
(AH) for 15 minutes (AH 15 min), pellets coated with AH for 60 minutes (AH 60 min), 
pellets coated with MH for 60 minutes (MH 60 min). For dissolution test, coated pellet 
samples (n = 3) were closed in hard gelatin capsule shells (size 1). 
 
The author suggest that the presence of a coating polymer, HPMC, plays a 
major role in improving the dissolution characteristics of PRX solid-state forms 
in drug-layer coated pellets. It is evident that hydrophilic HPMC could provide 
increased wettability of the drug-layer coatings thus accelerating the dissolution 
of a poorly water-soluble drug. It has been reported that HPMC may improve 
the solubility and dissolution along with in vivo bioavailability (Yamashita et 
al., 2003). As the drug-layer coating of pellets was not very thick, it could also 
be expected that an increased specific surface area increased a dissolution rate. 
Furthermore, in case of PRX solid-state forms as a powder, the possible 
agglomeration of the individual powder particles may decrease the effective 
surface area and thus slow down the dissolution rate. 
 
 
5.5. Biopharmaceutical relevance  
of solid state forms and their phase  
transformations-pharmacokinetic studies (I) 
As solid-state forms and solution-mediated phase transformations may change 
the oral bioavailability of poorly water-soluble APIs, the absorption of different 
PRX solid-state forms were compared. There were significant differences in 
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Figure 26. Plasma concentration profiles of different solid-state forms of piroxicam 
(PRX) after oral administration to rats (n = 6). Data are exhibited as mean (n=6)±S.E. 
 
The PRX plasma levels were much higher after an oral administration of SD 
and PM AH compared to those obtained after oral administration of AH and 
MH to rats. After oral administration of SD, absorption was the fastest being 
also significantly faster than that observed after oral administration of PM AH. 
Furthermore, the rate and extent of absorption of drug was found to be signi-
ficantly higher after oral administration of PM AH compared to that observed 
after oral administration of AH and MH. Also the rate of absorption of drug was 
found to be significantly higher after oral administration of AH compared to 
that observed after oral administration of MH. Several studies have investigated 
the effect of amorphous SD and presence of excipients on drug dissolution and 
presented clear advantages of amorphous SD in vitro (Sathigari et al., 2012; 
Tho et al., 2010), not so many have shown its relevance in the in vivo perfor-
mance of a drug. 
As seen in Table 2, significant differences were found in the key pharma-
cokinetic parameters obtained after oral administration of different PRX solid-
state forms to rats. The time to reach the maximum concentration tmax of drug 
ranged from 125 ± 18 minutes (SD) to 330 ± 67 minutes (MH). The mean time 
of tmax was clearly the shortest after oral administration of SD, and the 
difference to the other PRX forms was statistically significant. PM showed the 
second shortest tmax mean value. The lowest rate and extent of absorption (tmax 
and Cmax mean values) were found when AH and MH were administered by oral 
route to rats. Differences in the tmax and Cmax mean values, however, were not 
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statistically significant after oral administration of AH and MH to rats. 
Differences in the tmax mean values after oral administration of MH and PM 
(and SD) to rats were found to be statistically significant. Bioavailability of 
PRX after oral administration to rats has been previously studied by Gwak et 
al., 2005 (Gwak et al., 2005). In their study, the plasma PRX levels after oral 
administration of AH to rats were clearly lower being approximately half of 
those plasma levels obtained in our study. The difference can be explained by 
different dosing of PRX. 
 
Table 2. Pharmacokinetic parameters of piroxicam anhydrate I (AH), piroxicam 
monohydrate (MH), solid dispersion of AH and Soluplus® 1:4 (SD) and physical 
mixture of AH and Soluplus® 1:4 (PM AH). Data are expressed as mean (n=6) ± S.E. 
 AH MH SD PM AH 
tmax (min) 265±69 330±67 125±18 180±0 
Cmax (?g/ml) 31.9±5.0 29.1±2.8 90.1±2.9 90.9±5.2 
AUC0–12 (?g h/ml) 322.5±51.3 277.1±27.2 869.1±24.6 920.1±58.9 
t1/2 (h) 17.0±3.8 17.7±2.5 16.6±2.9 21.2±2.8 
Cl/F (l/h) 0.007±0.002 0.007±0.001 0.004±0.001 0.003±0.001 
Vd/F (l) 0.155±0.034 0.165±0.024 0.088±0.004 0.086±0.006 
 
As regards to AH and MH, differences between the plasma concentrations of 
drug were statistically significant up to 90 minutes indicating faster dissolution 
rate and absorption of AH compared to MH to rats. As shown in Figures 8, 9 
and 10, SD exhibited the highest rate and extent of dissolution in vitro, and this 
was in good agreement with the present results of the pharmacokinetic study 
with rats.  
Based on the present results, the ranking of PRX solid-state forms according 
to the rate of absorption (tmax) after oral administration to rats decreased in the 
order SD (amorphous PRX), PM AH, AH and MH. Interestingly, these results 
were somewhat contradictory to the dissolution test results with basket method 
that showed higher dissolution rate for AH than PM AH (Fig. 8). This dis-
crepancy is probably due to the differences in the solubilizing properties of 
Soluplus® in the hydrochloric acid buffer (pH 1.2) and gastrointestinal fluids of 
rat. In addition, the authors believe that these differences might also be 
explained by an interaction between the polymer and gelatin capsule that 
occurred during dissolution testing with basket method.  
As seen in Table 2, the half-life of PRX was similar in all four groups, and 
no statistically significant differences were found between the t1/2 mean values 
of different PRX solid-state forms after oral administration to rats. The mean 
values for Vd/F and Cl/F in the MH and AH groups were almost two times 
higher than those in the PM AH and SD groups, and this difference between the 
groups was statistically significant. This kind of discrepancy in the values of 
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Vd/F and Cl/F is quite expected since the values of AUC0-12 of PRX in PM 
and SD groups were almost three times higher than in the AH and MH groups. 
The highest mean values for plasma PRX concentration (Cmax) and AUC0–12 
were achieved after oral administration of PM AH and SD (Table 2). The mean 
values for Cmax in the MH and AH groups were almost three times lower than 
those in the PM AH and SD groups, and this difference was statistically signi-
ficant. The mean values for AUC0–12 were more than two times smaller after 
oral administration of AH and MH. Differences in the mean values for AUC0–12 
were statistically significant between these two groups (PM AH/SD and 
AH/MH) after oral administration to rats. However, there was statistically no 
difference in the Cmax and AUC0–12 mean values between PM AH and SD 
groups and between AH and MH groups. 
As the highest extent of absorption (Cmax and AUC0–12) was found after oral 
administration of PM AH and SD to rats it can be suggested that amorphous 
PRX exhibits significantly improved oral bioavailability compared to its 
crystalline counterparts, and that Soluplus® can act as a stabilizer and 
precipitation inhibitor of amorphous PRX in SD. Similar results have been 
obtained by Linn et al. (Linn et al., 2012) who have studied bioavailability of 
danazol, itraconazole and fenofibrate on beagle dogs in solid solutions and 
physical mixtures with Soluplus®.  
The presence of polymer in a PMs with PRX (PM AH) improved the 
dissolution and bioavailability in a lower extent compared to SD. These results 
indicate that the presence of amorphous PRX in SDs leads to increased 
dissolution. Although it was verified for SD that a rapid amorphous to MH 
solid-state transformation occurred in hydrochloric acid buffer (slurry test, 
publication I, Figure 11b), SD still provided the best bioavailability. It is likely 
that amorphous drug will dissolve rapidly and the solution becomes 
supersaturated with respect to crystalline MH without any crystallization (i.e., 
nucleation and crystal growth on the surface of amorphous drug). PRX as a 
BCS II drug has been reported to have a fast penetration (Ginski and Polli, 
1999). This implies that dissolved PRX is absorbed before any crystallization 
from solution occurrs. In addition, absorption decreases the concentration (and 
the possible degree of supersaturation) in the gastrointestinal tract, which in turn 
will decrease the probability of crystallization. Consequently, and for the 
reasons mentioned above, it is expected that most of the drug remaining in the 
dissolving solid sample is in the amorphous form during in vivo dissolution and 
absorption, although the crystallization occurred within similar timescales 
during the slurry and in vitro dissolution experiments. 
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6. CONCLUSIONS 
Present study enhanced the knowledge of water-mediated solid state trans-
formations taking place during processing and dissolution of API. Also the effect 
of given changes on the performance of the API was revealed in vitro and in 
vivo. 
1. Different solid state forms of a poorly water-soluble polymorphic drug 
piroxicam (PRX) were successfully prepared and it was possible to charac-
terize the forms with Raman spectroscopy, ATR-FTIR spectroscopy, DSC 
and XRPD. 
2. The solid-state forms can significantly influence the solubility and dis-
solution rate of PRX. The model drug exhibits a clear solid-state dependent 
dissolution. Amorphous PRX (in solid dispersion, SD) was shown to have an 
improved dissolution rate compared to its crystalline counterparts (PRX 
anhydrate form I, AH and monohydrate, MH). It was also discovered that 
different solid state forms have different stabilities in dissolution medium. 
MH and PRX in PM AH remained stable while AH and SD recrystallized as 
MH within 220 and 10 minutes, respectively. 
3. Different solid-state forms can significantly influence the oral bioavailability 
of a poorly water-soluble polymorphic drug. The present model drug (PRX) 
exhibits a clear solid-state dependent oral absorption in rats. Amorphous 
PRX (in SD) was shown to have an improved oral bioavailability compared 
to its crystalline counterparts AH and MH). Soluplus® enhanced the oral 
bioavailability of PRX in rats showing the importance of formulation (poly-
meric excipient) on oral bioavailability of a poorly water-soluble drug. 
4. The present SDs were physically stable in powder form under low humidity 
(~0% RH) and low to intermediate temperature (6 °C and 25 °C) conditions 
for at least six months. Aging at higher humidity (~40% and ~75% RH) and 
temperature (25 °C) caused amorphous PRX (in SDs) to crystallize as a AH 
or MH within one month and two to three months, respectively. In con-
clusion, high humidity storage conditions can greatly affect the solid-state 
properties (crystallization) and dissolution behavior of PRX formulated in 
SDs with Soluplus®. 
5. Principal component analysis (PCA) and multivariate curve resolution alter-
nating least squares (MCR-ALS) facilitated the qualitative and quantitative 
analysis of the Raman spectra obtained with the aged SD samples stored at 
different humidity and temperature conditions. 
6. Water-mediated solid-state process-induced transformations (PITs) of amor-
phous PRX can occur during aqueous-based drug-layer coating of pellets, 
and solid-state change can be verified using Raman spectroscopy. AH and 
MH were stable during drug-layer coating, but amorphous PRX in solid dis-
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persion (SD) crystallized as MH already after 10 minutes of coating. Raman 
spectroscopy also enabled to monitor the coating efficiency as the increase in 
absolute intensities of spectra matched with the weight gain. Coating effi-
ciency was mainly dependent on a drug-layer coating time; the longer coat-
ing times resulted in improved coating uniformity. Drug-layer coated pellets 
of PRX exhibited improved dissolution rate compared to the powder forms 
of PRX. 
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8. SUMMARY IN ESTONIAN 
Vee mõjul toimuvad polümorfse raviaine tahke vormi  
muutused – nende mõju ravimpreparaadi toimele 
Raviained võivad esined erinevate tahke aine vormidena (polümorfsed vormid, 
solvaatvorm, amorfne aine). Kristallilist ainet iseloomustab kindel korrapärane 
kolmedimensionaalne molekulide asetus struktuuris. Solvaatvormide puhul on 
lisaks raviaine molekulidele kristallstruktuuri kaasatud ka solvendi molekulid. 
Kui solvendi molekuliks on vesi, siis nimetatakse solvaatvormi hüdraadiks. 
Amorfsel ainel puudub kolmedimensionaalne kindel ja korrapärane molekulide 
asetus ja järjestatus struktuuris. 
Erinevad tahke aine vormid võivad omada erinevaid füsikokeemilisi oma-
dusi. Lahustuvus ja lahustumiskiirus on ühed olulisemad raviainete omadused, 
millest sõltub ravimpreparaadi biosaadavus ja toime organismis. Halb vesi-
lahustuvus ning sellest lähtuv aeglane imendumine organismis on üheks suure-
maks probleemiks ravimpreparaatide disainimisel, kuna järjest enam sünteesi-
takse vees vähe lahustuvaid uusi raviaineid. Püütakse leida erinevaid meetodeid, 
kuidas muuta raviaine omadusi ning parandada tema vesilahustuvust ning see-
läbi tema dissolutsioonikiirust ja biosaadavust. Üheks selliseks meetodiks on 
kiiremini ja paremini lahustuva tahke aine vormi kasutamine. 
Kui kasutada paremini lahustuvat tahke aine vormi, tuleb silmas pidada, et 
Burgeri reegli kohaselt on kõige paremat lahustumist omavad tahked vormid 
kõige ebastabiilsemad. On teada, et termodünaamiliselt on veevabas vormis 
olevad kristallilised raviained aktiivsemad kui hüdraatvormis ning suure tõenäo-
susega veevabad kristallvormid lahustuvad kiiremini kui hüdraadid. Amorfne 
raviaine omab kõige paremat näilist lahustuvust ja suuremat lahustumiskiirust, 
kuid olles väga ebastabiilne võib ta kergesti välja kristalliseeruda. Ka erine-
vused kristalliliste vormide (polümorfsete vormide, hüdraatvorm vs veevaba 
vorm) lahustuvustes ning lahustumiskiirusustes võivad olla raviaine in vivo 
imendumise ning biosaadavuste erinevuste põhjusteks. 
Niiskuse, temperatuuri ja mehaanilise survejõu mõjul toimuvad muutused 
farmatseutiliste protsesside ajal või ka säilitamisel erinevates tingimustes või-
vad indutseerida tahkes raviaines üleminekuid ühest vormist teise. Raviaine 
tahkes vormis toimuvate muutuste (näiteks hüdraadi tekkimine või amorfse vormi 
välja kristalliseerumine) tagajärjel võib oluliselt muutuda raviaine lahustumine 
ning biosaadavus organismis. Lisaks sellele võivad paljud abiained, mida kasu-
tatakse ravimpreparaatide tootmisel, muuta tahke raviaine käitumist ning oma-
dusi. On leitud, et osad abiained võivad suurendada raviaine lahustumiskiirust, 
teised aga võivad muuta raviaine dehüdratatsiooni kiirust. Samuti on leitud, et 
polümeerid suudavad stabiliseerida amorfseid raviaineid hoides ära nende 
kristallisatsiooni. Raviainete ja abiaine(te) vahelised interaktsioonid sõltuvad nii 
raviaine kui ka abiaine omadustest. On vaja välja uurida faasimuutuste mehha-
nisme nii in vitro kui ka in vivo tingimustes. On oluline välja selgitada, kuidas 
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erinevad abiained mõjutavad ja muudavad raviaine käitumist ja kas on võimalik 
abiainetega inhibeerida raviainega toimuvaid muutusi. Et disainida sobiv, 
stabiilne ja toimiv ravimvorm, on vaja juba preformulatsiooni käigus põhjalikult 
uurida raviaine omadusi ja tema interaktsioone abiainetega. 
Kuna amorfne raviaine lahustub kristallilistest vormidest sageli kiiremini ja 
annab üleküllastatud lahuse, siis on sellele pühendatud väga suur hulk farmat-
seutilist uurimistööd. Paraku on amorfse vormi suurimaks probleemiks tema 
ebastabiilsus. Ühe lahendusena sellele probleemile on pakutud amorfsete tah-
kete dispersioonide kasutamist. Amorfse tahke dispersiooni puhul on raviaine 
molekulaarsel tasemel dispergeeritud polümeerses kandjas. Enamasti on see 
polümeerne kandja amfifiilsete omadustega. Amorfsed tahked dispersioonid 
omavad puhta raviaine amorfse vormiga võrreldes suuremat stabiilsust. Sageli 
tekivad raviaine ja polümeeri molekulide vahel vesiniksidemed, mis vähen-
davad termodünaamilist potentsiaali ja seega ka amorfse aine tendentsi välja 
kristalliseeruda. Polümeerne abiaine toimib ka kineetilise barjäärina takistades 
raviaine molekulide lähenemist distantsini, kus saaks tekkida kahe raviaine 
molekuli vahel vesinikside. Seega takistab polümeer tahketes dispersioonides 
kristallisatsioonikeskmete teket ja nende kasvamist. Amfifiilsete omadustega 
polümeerid on farmaatsias eelistatud, kuna need suudavad stabiliseerida amorf-
sest tahkest dispersioonist tekkivat üleküllastunud lahust läbi solubilisatsiooni. 
Antud uurimistöös kasutatakse raviainena piroksikaami, mis on vees vähe-
lahustuv kuid gastrointestinaaltraktist kiiresti absorbeeruv aine. Piroksikaamil 
on leitud kolm polümorfset vormi, monohüdraatvorm ja teda on võimalik saada 
ka amorfse vormina. Polümorfsetest vormidest on tavatingimustes kõige stabiil-
sem I vorm (AH), vesikeskkonnas on kõige stabiilsemaks vormiks aga mono-
hüdraat (MH). Amorfset piroksikaami on võimalik valmistada näiteks vitri-
fikatsioonil, kuid on teada, et see on väga ebastabiilne ja kristalliseerub AH-na 
välja. Samuti on vitrifikatsioonil amorfse vormi valmistamine piroksikaami 
puhul problemaatiline, kuna sellega kaasneb osaline degradatsioon. 
Polüvinüülkaprolaktaam-polüvinüülatsetaat-polüetüleeneglükool graft kopo-
lümeer (Soluplus®) on spetsiaalselt tahkete dispersioonide valmistamiseks 
mõeldud uudne abiaine. Antud uurimistöös kasutati seda stabiliseerimaks 
piroksikaami amorfses vormis. Soluplusi® iseloomustab amfifiilne olemus ja 
klaasistumistemperatuur 68 °C. Soluplus® on võimeline absorbeerima õhu-
niiskust. 40% suhtelise õhuniiskuse juures 4% ja 75% õhuniiskuse juures 12% 
massist. Farmatseutilises mõttes on oluline ka Soluplusi® hägustumistem-
peratuur, mis on 40 °C. Elektrolüütide lisamisel lahustesse võib see langeda ja 
põhjustada antud polümeeriga valmistatud ravimvormi disintegratsiooni aeg-
lustumist. 
Kuna nii säilitamise, kui ka lahustumise ja farmatseutiliste protsesside ajal 
võivad esineda tahke aine vormi muutused, siis on oluline raviaine tahket vormi 
nende protsesside ajal jälgida. Järjest enam on hakatud farmaatsias tahke aine 
muutuste jälgimiseks kasutama võnkespektroskoopilisi meetodeid. Antud mee-
todid on mitte-invasiinsed ja kiired ning võimaldavad saada infot raviaine 
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muutuste kohta juba molekulaarsel tasemel. Kuna antud analüütiliste meeto-
ditega kogutud spektrite analüüsimine võib olla suure saadava andmemahu tõttu 
keeruline, kasutatakse neid laialdaselt kombinatsioonis mitmemõõtmeliste 
andmeanalüüsi meetoditega- kemomeetriliste meetoditega. Neist levinuim on 
peakomponent analüüs (PCA), mis võimaldab kergelt illustreerida ja analüüsida 
spektrites olevat olulist informatsiooni. PCA on matemaatiline toiming, kus 
muudetakse suures andmestikus esinevad omavahel korrelatsioonis olevad 
spektrite erisused väikese arvulisteks ja kergelt hoomatavateks peakompo-
nentideks, mis pole omavahel korrelatsioonis. Iga mudeli poolt tekitatud pea-
komponent sisaldab endas ja kirjeldab spektrites esinevaid erinevusi. See muu-
dab muutuste jälgimise suurte andmemahtude puhul märgatavalt lihtsamaks. 
Selleks, et kvantifitseerida tahke aine vormi muutuseid on võimalik kasutada 
näiteks mitmemõõtmelist kõverate lahutust. See meetod lahutab ainete segudest 
mõõdetud spektrid koostisosade spektriteks ja selle alusel arvutab välja segu 
komponentide kontsentratsioonid. 
Antud uurimustöös keskenduti piroksikaami tahke aine vormide (veevaba 
piroksikaami I vorm (AH), piroksikaam monohüdraat (MH), piroksikaami ja 
Soluplusi® amorfne tahke dispersioon vahekorras 1 osa 4-le (SD)) muutuste 
uurimisele nii pikaajalise säilitamise, lahustumise ajal kui ka farmatseutilise 
protsessi ajal (pelletite katmise näitel). Samuti tehti kindlaks antud muutuste 
olulisus nii in vitro dissolutsioonitesti ajal kui in vivo loomkatsetes. Selleks, et 
teha kindlaks Soluplussi® enda toime raviaine käitumisele, kaasati uurimis-
töösse ka kristallilise piroksikaam AH ja Soluplussi® heterogeenne segu vahe-
korras 1 osa 4-le (PM AH). Uurimistöö tulemused annavad võimaluse aru saada 
raviaine tahke vormi muutustest ja selle olulisusest ravimpreparaadi kvaliteedile 
ja toimele organismis. 
 
 
UURINGU EESMÄRGID 
Käesoleva uurimistöö spetsiifilised eesmärgid olid järgmised: 
- Valmistada ja tuvastada erinevad piroksikaami tahke aine vormid 
- Teha kindlaks piroksikaami erinevate tahke aine vormide mõju raviaine in
vitro lahustumiskiirusele ja teha kindlaks piroksikaami erinevate tahke aine 
vormide stabiilsus lahustumiskeskkonnas 
- Teha kindlaks piroksikaami erinevate tahke aine vormide in vivo biosaada-
vus rottidel 
- Teha kindlaks piroksikaami ja Soluplusi® tahke dispersiooni füüsikaline 
stabiilsus säilitamisel ja teha kindlaks võimaliku kristallisatsiooni mõju 
lahustumisele. 
- Viia läbi antud tahke dispersiooni rekrisalliseerumise kvalitatiivne ja 
kvantitatiivne analüüs kasutades vastavalt peakomponent analüüsi ja mit-
memõõtmelist kõverate lahutamist. 
- Teha kindlaks piroksikaami tahke aine vormide stabiilsus pelletite katmisel 
antud tahke aine vormide suspensioonidega. 
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MATERJALID JA MEETODID 
AH-d kasutati tootja (Letco Medical inc., USA) poolt saadud vormis ning MH 
saadi AH ümberkristalliseerimisel kuumast veest. SD valmistati lahusti aurus-
tamise meetodil. Selleks lahustati AH ja Soluplus® atsetoonis ning saadud segu 
aurutati kuivaks 40 °C juures. PM AH valmistati AH ja Soluplusi® segamisel 
uhmris kasutades geomeetrilise lahjenduse põhimõtet.  
Tahke aine vormid tehti kindlaks kasutades Raman spektroskoopiat, Fourier 
transformeerivat infrapuna spektroskoopiat (FTIR), pulberröntgendifrakto-
meetriat (XRPD) ja diferentsiaalset skaneerivat kalorimeetriat (DSC). 
Pulbri vormis tahke ainete lahustumiskiirus ja tahke aine vormide vabane-
mine kapslitest tehti kindlaks dissolutsioontesti esimese ja teise meetodiga. 
Raviaine kontsentratsioon lahuses määrati UV spektrofotomeetriga. Uurimaks 
raviaine stabiilsust vabanemiskeskkonnas viidi läbi katse, kus raviaine tahke 
aine vormide stabiilsus kontsentreeritud suspensioonidena tehti kindlaks Raman 
spektroskoobi abil. 
Lühiajaline säilitamiskatse (6 kuud) viidi läbi neljas erinevas keskonnas: 
~0% RH / 6°C, ~0% RH / 25°C, ~40% RH / 25°C ja ~75% RH / 25°C. Proove 
analüüsiti kasutades Raman spektroskoopiat ja FTIR spektroskoopiat. Raman 
spektrite andmeanalüüs viidi läbi kasutades peakomponent analüüsi ja mitme-
mõõtmelist kõverate lahutamist. 
Mikrokristallilisest tselluloosist pelletite katmine raviaine suspensioonidega 
(sisaldas 4% raviainet kristalliliste vormide puhul ja 2% SD puhul) viidi läbi 
miniatuurse katmismasinaga. Katmissuspensioonidele oli lisatud 5% (w/w) 
hüdroksüpropüülmetüültselluloosi. Pelletite pinnal oleva tahke aine vormi 
määramiseks katmise ajal kasutati Raman spektroskoopiat. Pelletite pinna-
omaduste uurimine viidi läbi skaneeriva elektronmikroskoobiga (SEM). 
Piroksikaami tahke aine vormide biosaadavuse uuring viidi läbi kasutades 
isaseid Wistar rotte. Igas katsegrupis oli 6 rotti. Piroksikaami tahke aine vormid 
manustati suspensioonina kasutades maosisest sondi. Vereplasma kontsentrat-
sioonid tehti kindlaks kasutades kõrgefektiivset vedelikkromatograafiat. 
 
 
UURINGU TULEMUSED JA ARUTELU 
Piroksikaami tahke aine vormide tuvastamiseks kasutati XRPD, Raman spekt-
roskoopiat, FT-IR spektroskoopiat ja DSC. XRPD abil mõõdetud AH ja PM AH 
difraktogrammid vastasid Cambridge struktuuride andmebaasi (CSD) alusel 
arvutatud teoreetilisele AH difraktogrammile ja MH difraktogramm vastas teo-
reetilisele MH difraktogrammile. Selle alusel võib järeldada, et meie poolt 
kasutatavad tahke aine vormid vastasid eeldatavatele vormidele. SD difrakto-
grammi alusel oli võimalik tuvastada piroksikaami amorfne vorm, kuna esines 
iseloomulik amorfne “halo”– puudusid iseloomulikud kristallilise aine peegel-
dused difraktogrammis. Lisaks oli võimalik tuvastada piroksikaami tahke aine 
vormid kasutades Raman spektroskoopiat ja FTIR spektroskoopiat. Mõlema 
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meetodi puhul ilmnesid spektrites muutused, mis vastasid kirjanduses varem 
kirjeldatudele. Infrapuna spektroskoopia võimaldas tuvastada ka vesinikside-
mete tekkimise piroksikaami ja Soluplusi® vahel SD-s. Vesiniksidemete esine-
mine piroksikaami ja Soluplusi® molekuli vahel viitab sellele, et tekkis mole-
kulaarsel tasemel dispersioon. Samuti lubab see eeldada amorfse faasi para-
nenud füüsikalist stabiilsust. 
Kõige kiiremini vabanes dissolutsioonitestides kapslitest piroksikaami tahke 
aine vormidest SD. Raviaine vabanemiskiiruselt paremuselt teine tulemus oli 
võimalik saavutada AH-ga ja kõige aeglasem vabanemiskiirus saavutati, kui 
kasutati MH-d. PM AH puhul jäi vabanemise kiirus AH ja MH vahepeale. Selle 
alusel võib väita, et amorfne vorm võimaldas oluliselt kiirendada raviaine lahus-
tumist. MH kõige aeglasem lahustumine oli eelduspärane, kuna on teada, et MH 
on vesikeskkonnas kõige stabiilsem vorm, mistõttu peaks tal olema kõige 
madalam lahustuvus ja kõige aeglasem lahustumine. 
Piroksikaami tahke aine vormide füüsikalise stabiilsuse uurimiseks lahus-
tumiskeskonnas viidi läbi vastavate suspensioonide uurimine kasutades Raman 
spektroskoopiat. Testi tulemusel tuvastati, et SD-st kristalliseerub piroksikaam 
MH välja 10 minuti jooksul. AH puhul toimub see protsess 220 minuti jooksul. 
AH rekristalliseerumist iseloomustab viite-aeg 80 minutit, mis kulub MH suhtes 
üleküllastatud lahuse tekkimisele. MH ja PM AH olid antud katse tingimustel 
stabiilsed kaheksa tunni jooksul. Seega Soluplus® ei ole võimeline stabili-
seerima piroksikaami amorfset vormi väga üleküllastunud lahuse puhul, küll 
aga on ta võimeline stabiliseerima veevaba AH vastavatel tingimustel. Võimalik 
kristallisatsioon võib ka selgitada SD lahustumise teatavat aeglustumist 
dissolutsioonitestides. 
In vivo biosaadavuse katse viidi läbi manustades rottidele (n=6) piroksikaami 
tahke aine vorme vesi-suspensioonina kasutades maosisest sondi. Kõige kiirem 
vereplasma maksimumkontsentratsioon saavutati SD puhul (125±18 minutit). 
Erinevalt in vitro dissolutsioonitestidest saavutas kiiruselt teise tulemuse PM 
AH (180±0 minutit). Vereplasma maksimumkontsentratsiooni saavutamise kii-
ruselt kõige aeglasema tulemuse andis MH (330±67 minutit). AH andis plasma 
maksimum kontsentratsiooni saavutamise kiiruse mõttes vahepealse tulemuse 
(265±69 minutit). Vereplasma maksimum kontsentratsioonilt olid SD ja PM 
AH peaaegu samaväärsed, samas, kui AH ja MH andsid umbes kolm korda 
madalama maksimum kontsentratsiooni. Samuti oli SD ja PM AH biosaadavus 
uuritava ajavahemiku jooksul (AUC0–12) umbes kolm korda kõrgem, kui AH-l ja 
MH-l. Kuna piroksikaam on halvasti lahustuv kuid kiiresti absorbeeruv ravi-
aine, siis on eelduspärane, et kõige kiiremini lahustuv ravimvorm annab ka 
kõige kiiremini vereplasmas maksimum kontsentratsiooni. Vereplasma maksi-
mum kontsentratsiooni ja biosaadavuse kolmekordse erinevuse tõenäoliseks 
põhjuseks on SD ja PM AH ravimvormides olev Soluplus®. Kuna roti seede-
kulglas on vedeliku maht suhteliselt väike, siis arvatavasti Soluplussi ® solubili-
seerivad omadused mõjutavad oluliselt biosaadavust organismis. 
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Uurimaks SD füüsikalist stabiilsust säilitati proove erinevate õhuniiskuse 
tingimustes kuni kuus kuud. Teatud kindlates ajapunktides koguti proovide 
Raman ja FTIR spektrid. Selleks, et viia läbi füüsikalise stabiilsuse katse and-
mete analüüs kasutati peakomponentanalüüsi ja mitmemõõtmelist kõverate 
lahutamist. Peakomponentanalüüs võimaldas läbi viia kvalitatiivse analüüsi ja 
mitmemõõtmeline kõverate lahutamine võimaldas läbi viia kvalitatiivse ana-
lüüsi. SD oli ~0% suhtelise õhuniiskuse juures stabiilne vähemalt kuus kuud. 
~40% suhtelise õhuniiskuse juures oli võimalik tuvastada SD kristalliseerumine 
AH-na neli päeva peale katse algust. ~75% õhuniiskuse juures oli tuvastatav SD 
kristalliseerumine AH-na juba esimese päeva jooksul. Kuu aega peale katse 
algust oli tuvastatav SD kristalliseerumine MH-na. Kuna kõrgema õhuniiskuse 
juures absorbeeritud vesi võib käituda plastifikaatorina suurendades polümeeri 
ahelate liikumist, siis see võib vähendada Soluplussi® stabiliseerivaid omadusi, 
mistõttu toimus raviaine välja kristalliseerumine tahkest dispersioonist. 
Uurimaks raviaine tahke vormi füüsikalist stabiilsust farmatseutilise toot-
misprotsessi ajal viidi läbi katse, kus mikrokristallilisest tselluloosist pelleteid 
kaeti piroksikaami tahke aine vormide vesi-suspensioonidega. Tahke aine vormi 
füüsikalist stabiilsust uuriti kasutades Raman spektroskoopiat. Kui AH ja MH 
jäid katmisprotsessi ajal stabiilseks, siis SD kristalliseerus välja katmise-
protsessi esimese kümne minuti jooksul MH-na. AH võime säilitada oma vee-
vaba kristallvorm vesikeskkonnas on selgitatav katte kuivamise piisava kiiru-
sega, mistõttu ei jõudnud rekristallisatsioon toimuda. Samuti võis omada stabili-
seerivat toimet katmissuspensioonis sisalduv hüdroksüpropüülmetüültselluloos. 
Kui AH ja MH-ga läbi viidud katmisprotsessi tulemusena saadi ühtlane kate, 
siis SD-ga kaetud pelletitest tehtud SEM piltidel oli näha pelletite pinnal suuri 
defekte. Tekkinud katte ebaühtlus on selgitatav Soluplussi® kohesiivsete 
omadustega, mistõttu ei omanud pelleti pinnal tekkiv kate piisavat plastilisust, 
et protsessi käigus tasanduda. 
Kõige kiiremini vabanes raviainet AH-ga kaetud pelletitest. See oli isegi kii-
rem, kui amorfse piroksikaami vabanemine kapslitesse paigutatud SD-st. Selle 
tõenäoliseks põhjuseks oli see, et kate pelletite peal oli suhteliselt õhuke, mis-
tõttu aine eripind oli üsna suur. Samuti võis lahustumisele kaasa aidata katte 
koostises olev hüdroksüpropüülmetüültselluloos. Kõige aeglasemalt vabanes 
raviaine SD-ga kaetud pelletitetelt. See oli ka eeldatav, kuna oli toimunud 
amorfse aine välja kristalliseerumine MH-na ja katte koostises olev Soluplus® ei 
disintegreeru antud tingimustes. 
 
 
JÄRELDUSED 
- Kasutatud meetoditega õnnestus valmistada ja tuvastada erinevad piroksi-
kaami tahke aine vormid 
- Kõige paremad lahustumisomadused olid amorfsel piroksikaamil tahkes 
dispersioonis. Kõige halvemad lahustumisomadused olid MH-l. AH ja 
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amorfne piroksikaam olid lahustumiskeskkonnas ebastabiilsed kristalliseeru-
des MH-na vastavalt 10 ja 220 minuti jooksul.  
- Kõige parem biosaadavus ja kõige kiirem vereplasma kontsentratsioon rotti-
del saavutati SD-ga. PM AH andis paremuselt teise tulemuse, samas kui MH 
oli kõige madalama biosaadavusega ja samuti saabus MH puhul vereplasma 
maksimum kontsentratsioon kõige aeglasemalt. 
- Piroksikaami ja Soluplussi® tahke dispersioon oli füüsikaliselt stabiilne 
madala õhuniiskusega tingimustes säilitamisel. Keskmise ja kõrge suhtelise 
õhuniiskusega tingimustel toimus amorfse piroksikaami kristalliseerumine 
vastavalt AH ja MH-na.  
- Peakomponent analüüsi ja mitmemõõtmeline kõverate lahutamine võimal-
dasid viia läbi antud tahke dispersiooni krisalliseerumise kvalitatiivne ja 
kvantitatiivne analüüs. Proovides, kus oli toimunud kristallisatsioon vähenes 
lahustumiskiirus märgatavalt võrreldeds SD-ga. 
- AH ja MH olid stabiilsed pelletite katmisel samas kui SD kristalliseerus 
MH-na. 
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